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ABSTRACT 
Peptide and protein drugs are increasingly becoming popular 
with the advances in biotechnology. Although these compounds are 
highly potent and display superior pharmacological profiles, there 
are various barriers to their systemic delivery. Most of these barriers 
are related to the properties of the proteins and peptides which 
include high large molecular size, susceptibility to proteolytic 
breakdown, tendency to undergo aggregation, adsorption, and 
denaturation. 
Most of these molecules are delivered by parenteral 
administration due to the low bioavailability obtained by the oral 
route. Among the noninvasive routes of drug administration, the 
nasal route seems to be a potential alternative to parenteral 
administration of peptides and proteins. 
When compared to other noninvasive routes of administration, 
the nasal route offers some advantages; including avoidance of the 
first pass effect and enzymatic degradation in the gastrointestinal 
tract; and a relatively large surface area and adequate blood flow, 
resulting in rapid absorption of drugs through the nasal mucosa and 
providing high patient compliance. However, there are certain factors 
which could interfere with the nasal absorption of drugs such as the 
method and technique of administration , and pathological conditions 
of the nasal cavity. 
Surprisingly few animal models have been developed and 
characterized to study the basic physicochemical nature of the nasal 
mucosal absorption processes, in spite of the great potential offered 
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by the intranasal route for systemic drug administration. Most of the 
mechanistic and absorption screening studies have been performed 
using the in situ rat nasal recirculation technique. The small nasal 
cavity and nostrils of the rat restrict the evaluation of nasal 
formulations such as metered sprays, powders and microspheres. 
The acute nature of the perfusion technique limits its application to 
small laboratory animals for economic reasons. Hence there is a need 
to develop chronic perfusion techniques in large laboratory animals 
which can give better representation of the nasal mucosal absorption 
processes in human beings. 
The objectives of this study were: (1) to develop and establish 
a non-surgical perfusion technique for use with large laboratory 
animals, (2) to compare the new technique with the existing 
techniques, (3) to identify the study conditions to establish and 
validate the animal model, ( 4) to evaluate various nasal formulations 
and/or modes of administration such as sprays, microparticles usmg 
the same animal model and compare with the results obtained from 
perfusion studies. 
Insulin was chosen as model polypeptide and the rabbit was 
selected as an animal model. A randomized crossover study design 
was used for evaluating the insulin effect in five rabbits. The 
absorption of insulin was measured by determining blood glucose 
levels using Accu chek II and ChemStrip bG strips. 
A new non-surgical perfusion technique was developed and 
established using the rabbit. The study conditions identified in 
establishing the animal model include: the angle at which the rabbit 
head is placed, the perfusion rate, the volume of the perfusate, the 
111 
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amount of the enhancer present in the perfusate and the pH of the 
solution. Spray formulations containing different levels of insulin 
(1.25, 2.5, 5 and IOU/kg) and sodium taurocholate (1 %) were 
evaluated in the same animal model. The nasal sprays resulted m an 
immediate reduction of glucose levels. A maximum hypoglycemic 
effect was observed approximately 60 minutes after administration. 
As the insulin dose was increased, there was an increase in glucose 
reduction. A polyacrylic acid gel formulation containing insulin 
loaded microparticles (lOU/kg) resulted in a hypoglycemic effect, but 
the overall effect was less when compared to the spray formulations 
and s.c injection. 
The apparent bioavailability was determined relative to 
subcutaneously injected insulin (0.25U/kg). This bioavailability 
increased for spray formulations as the dose of insulin was 
decreased. A maximum bioavailability of 18.8% was observed for the 
1.250/kg spray and the minimum bioavailability (1.58%) was 
observed for the perfusion study carried out using the new 
technique. 
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1. INTRODUCTION 
1.1 Introduction 
With the advance of biotechnology, peptide and protein drugs 
are increasingly becoming popular. However, the technology for the 
manufacture of proteins and peptides has advanced far more rapidly 
than our ability to deliver these molecules in appropriate and 
convenient dosage forms (Sandow et al., 1987; Davis, 1989). Although 
these types of compounds are highly potent and display superior 
pharmacological profiles, there are a number of barriers to their 
systemic deli very. Most of these barriers are related to the 
properties that set proteins and peptides apart from the vast 
majority of drug substances in use today. These properties include 
molecular size, susceptibility to proteolytic break down, rapid plasma 
clearance, peculiar dose response curves, immunogenicity, 
biocompatibility and the tendency to undergo aggregation, 
adsorption, and denaturation (Lee, 1988; Borchardt et al., 1989). 
The oral route is the most popular means of delivering drug 
molecules as it provides many advantages. However, proteins and 
peptides when given orally produce very poor bioavailability, 
because these molecules are easily degraded by proteolytic enzymes 
in the gastrointestinal tract and are generally not well absorbed. 
Currently, they are mostly delivered by parenteral administration. 
However, they often have an extremely short biological half-life 
when administered parenterally and repeated injections are needed. 
This type of therapeutic regimen is highly risky to administer 
without close medical supervision. It is often difficult for most 
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patients to accept and this leads to reduced usage and a low rate of 
compliance. The commercial success of protein and peptide drugs will 
depend on the development of either non-parenteral routes of 
administration such as nasal, rectal, buccal, pulmonary, vaginal, 
ophthalmic and transdermal or on the successful development of 
other novel parenteral approaches such as implantable delivery 
systems (Banga et al., 1988; Lee, 1988). 
Compared to other routes, the buccal mucosa offers a large and 
easily accessible area for placement of delivery systems such as 
adhesive tablets, gels, and patches. However, the low bioavailability 
observed for various proteins and peptides indicate that the buccal 
mucosa is not very permeable to macromolecules (Lee, 1988). 
Consequently, further work is required to determine whether .he 
bioavailability of these molecules can be improved through the 
manipulation of delivery systems. 
Solutions, gels, and suppositories are conventional dosage forms 
for rectal and vaginal delivery of peptides and proteins (De Boer et 
al., 1990). Gel formulations seem to be the most efficient because 
they offer a proper balance between retention at the site of 
administration and the rate of peptide release. Though these routes 
offer a promising potential for delivery of peptides and proteins, low 
patient compliance is the major hurdle. 
The ocular membrane can also be used for the systemic 
delivery of therapeutic peptides and proteins (Banga et al., 1988). 
Systemic delivery via the ocular route relies on overflow of the 
instilled eye drops and nasolacrimal duct absorption. Some of the 
approaches which have been found useful in enhancing the ocular 
2 
( absorption of peptides and proteins include use of nanoparticles, 
liposomes, gels, inserts, latex systems, bioadhesives and surfactants 
(Chiou et al., 1989). In addition to the permeation barrier, the 
presence of peptidases in ocular tissues limit the absorption of intact 
peptide and protein drugs. This route of administration is not likely 
to become popular for systemic delivery since the bioavailability is 
extremely low. Also, ocular tissues are extremely sensitive to foreign 
substances and patient compliance could be rather low. 
Compared to mucosa! routes, the transdermal route shows 
greater resistance to peptide and protein absorption, primarily 
because of the impermeability of the stratum corneum. Iontophoresis 
is now being actively investigated to overcome this deficiency. 
Results indicate limited success with significant inter-animal 
variation (Lee, 1991). These contradicting results coupled with the 
uncertain long-term effect of applied current on the well-being of 
the skin, cast doubt on the viability of iontophoresis as a nomnvas1ve 
technique to improve transdermal peptide and protein delivery. 
Among the non-invasive routes of drug administration, the 
nasal route seems to be a potential alternative to parenteral 
administration of peptides and proteins (Lee et al., 1988; Lee, 1988; 
Chien et al., 1989; Harris, 1989). 
Historically, use of nasal route for drug delivery has received 
the attention of mankind smce ancient times. Nasal therapy, also 
called " Nasaya Karma" has been a recognized form of treatment m 
the Ayurvedic system of Indian medicine for many centuries. 
Psychotropic drugs and hallucinogens have been used as a nose snuff 
by the Indians of South America (Chien et al., 1985). Use of the nasal 
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route to deliver peptides systemically dates back to 1922 (Chien et 
al., 1985). Since then, many attempts have been made to deliver 
peptides and proteins nasally. In recent years, the nasal route has 
received a great deal of attention as a viable alternative to the 
parenteral route for delivering proteins and peptides (Lee et 
al., 1988). 
When compared to other routes of administration, the nasal 
route offers many advantages. In addition to its accessibility for 
systemic drug delivery, the nasal cavity offers both pharmacokinetic 
and pharmaceutical advantages. It offers the advantage of by-
passing the metabolic elimination pathways of gastrointestinal tract 
and liver and thereby significantly reducing first pass metabolism. 
The nasal mucosa offers a large surface area and relatively low 
enzymatic degradation resulting in the rapid absorption of drug 
molecules. Thus the pharmacokinetics of intranasal administration 
are characterized by rapid absorption into the systemic circulation 
producing high plasma levels similar to those witnessed after I. v. 
administration. Intranasal administration 1s a convenient and easy 
form of self-administered non-invasive therapy and should enjoy a 
high level of patient compliance. 
However, there are certain factors that limit the exploitation of 
nasal route for systemic absorption of peptide and protein drugs 
(Chien et al., 1989; Pontiroli et al., 1990). Rapid clearance of the 
surface mucous coat in the nose shortens the time available for drug 
absorption. The permeability of the nasal membrane is dependent on 
the size of drug molecules. Due to their high molecular size, peptides 
and proteins often need permeation enhancers to increase their 
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bioavailability. These enhancers may destroy the mucous membrane 
and disrupt the nasal functions. Nasal preparations are not amenable 
to formulation manipulation. Other factors that should be considered 
m optimizing dosage regimens for nasal administration are, the 
methods and techniques of administration and the existence of any 
pathological conditions which may affect nasal function significantly. 
1.2 Nasal Physiology 
The nasal passage has three physiological functions (Geurkink, 
1983 ). It serves as (a) particle barrier to and a collector of inspired 
dust, allergens, and microorganisms; (b) as a heat exchanger and 
humidifier of air on its way to the lungs; and (c) as an organ of 
olfaction. 
The nasal passage which runs from the nasal vestibule to the 
nasopharynx has a depth of approximate! y 12-14 cm. There are 
three distinct functional zones in the nasal cavity: namely, vestibular, 
respiratory, and olfactory areas (Jafek, 1983; Geurkink, 1983; Chien 
et al., 1989). The vestibular area serves as a baffle system, and its 
surface is covered by a common pseudostratified epithelium whose 
long hairs provide the function of filtering airborne particles. The 
respiratory area has a surface lined by a pseudostratified columnar 
epithelium, and is normally covered by a dense layer of mucus that 
is constantly moving towards the posterior apertures of the nasal 
cavity by a powerful system of motile cilia. The olfactory region is 
about 10 cm2 . The olfactory airway lies between the nasal septum 
and the lateral wall of the main passage. 
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The anterior nares mark the beginning of the double nasal 
airway, which extends from the entrance at the nostrils to the 
beginning of ciliated mucosa at the anterior ends of the nasal septum 
and turbanates. The main nasal passage extends backward by 
approximately 6 to 8 cm to the posterior ends of the turbanates and 
the arch of the septum. 
The nasal mucous membrane, lining the entire nasal cavity, can 
be divided into olfactory and nonolfactory epithelia. The nonolfactory 
epithelium is a highly vascular tissue that is covered by 
pseudostratified columnar, ciliated epithelium. The olfactory 
epithelium is a pseudostratified columnar in type, and consists of 
specialized olfactory cells, supporting cells, and both serous and 
mucous glands. 
There are two types of mucus covenng the surface of the 
mucous membrane: one adheres to the tips of cilia, and the other fills 
the space among the cilia. Three cell types- columnar, goblet, and 
basal - make up the mucous membrane, as shown in the Figure 1. 
Columnar cells, either ciliated or nonciliated are covered with 
microvilli on their apical surfaces. Goblet cells secret the mucin used 
in coating the epithelial layer with a protective mucus layer. Basal 
cells are developing, undifferentiated columnar or goblet cells and do 
not extend into the nasal cavity. 
Nasal mucociliary activity is one of the most important 
physiological defense mechanisms of the respiratory tract used to 
protect the body against any inhaled noxious materials (Geurkink, 
1983 ). The mucous blanket consists of two layers. The outer layer is 
6 
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Figure 1. Microscopic view of vanous cell types in the nasal 
epithelium. I-nonciliated columnar cell with microvilli, II-goblet cell 
with mucous granules and Golgi apparatus, III-basal cell, IV-ciliated 
columnar cell with mitochondria in the apical part, OM-double 
membrane, CTM-convective tissue membrane. 
Source: Chien et al., 1989. 
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relativel y visco us and re sts on a thin layer of sero us fluid that tends 
to facilitate the action of the underlying cilia. The fine particulate 
matter that enters the inspired air is filtered by the process of 
adhering to the mucous film. 
In general, nasal mucociliary clearance carries auway 
secretions backward to the nasopharynx. This material is dispatched 
by a wiping action of the palate to the stomach periodically through 
swallowing. However, there is an area in the anterior nares of the 
inferior turbinate from which mucociliary clearance moves material 
forward, and this provides a clearance of deposited foreign materials 
from the body by nose blowing and wiping. Nasal clearance proceeds 
at an average rate of about 1 cm/min. Thus the mucous blanket is 
replaced every 10 to 15 minutes. A total of approximately 1500-
2000 ml of mucous is produced daily, and contains 90-95% water, 1-
2% salt, and 2-3% mucin. The functions of mucus include : (a) acts as 
a retainer for substances in the nasal duct; (b) behaves as an 
adhesive; (c) has water-holding capacity; (d) transports particulate 
matter; (e) exhibits surface electrical activity; (f) protects the mucosa; 
(g) acts as a mesh with specific permeability; and (h) allows heat 
transfer. It has been reported that the nasal epithelium may be 
altered- to produce excess mucus by a variety of agents, including 
gases, viruses, bacteria and certain diseases such as allergic rhinitis 
(Chien et al., 1989). 
Pathological conditions may impau mucociliary function. Drying 
of the nasal mucous membrane will cause cessation of ciliary activity 
while prompt moistening will restore its normal activity. The 
optimum temperature range for ciliary activity is 28 -30 oc. 
8 
( Hypotonic saline solutions will inhibit ciliary activity; hypertonic 
saline solutions will cause it to stop. It has also been reported that 
certain drugs such as adrenaline, cocaine and a number of other 
drugs or chemicals will interfere with ciliary activity (Chien et al., 
1989). 
Nasal secretions contain certain enzymes which cause 
degradation of drugs especially peptides and proteins. These are 
cytochrome P-450- dependent monooxygenase, lactate 
dehydrogenase, oxidoreductase, leucine aminopeptidase and 
phosphoglucomutase (Chien et al., 1989). 
1.3 Deposition and Clearance of Drugs From the Nasal Cavity 
The site of deposition within the nasal cavity depends upon the 
delivery system used and the technique of administration applied. 
The standard method of administration has been in the form of 
sprays or drops being delivered using rhinyl catheters, single dose 
pipettes and metered dose spray pumps (Su, 1989). The rhinyl 
catheter was the first system to be introduced and has the 
advantage that the catheter is graduated for different doses as 
required by the patient. The advantage of the disposable pipette is 
that it is suitable for single dose administration and therefore does 
not require addition of a preservative which is one of the most 
singular cause of nasal irritation and allergic rhinitis in patients on 
long term nasal therapy. The spray pump is simple to use and allows 
multiple dosing of any given dose. The site of deposition and the rate 
of clearance of the drug from nasal cavity will influence the efficacy 
of the dose received by the patient. 
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( A study by Aoki & Crawley ( 1976) compared the deposition 
and clearance of relatively large volumes of solution (0.1-0.75 ml) 
applied as nasal sprays and drops. It was found that greater 
coverage of the walls of the nasal cavity was achieved following 
administration of drops. It was also observed that the clearance rates 
were similar following both methods of administration and for all 
dosing volumes. 
The clearance of drug from the nasal cavity is a biphasic 
phenomenon; a rapid initial clearance followed by slow clearance. In 
another study (Hardy et al., 1984) Technetium -99m labeled human 
serum albumin was administered into the human nose by a nasal 
spray or nose drops. Forty percent of the dose was cleared rapidly 
with average half times for clearance ranging from 6 to 9 minutes. 
Following this rapid phase, clearance of the spray was much slower 
than drops, because most of the spray was deposited on the 
nonciliated regions, whereas the solution from the nose drops spread 
more extensively over the ciliated areas of the nose. 
Harris ( 1989) reported that the deposition pattern rn nasal 
cavity is dependent of the mode of administration. Desmopressin 
solution was administered as sprays using two types of metered 
spray pumps or as drops using a rhinyle catheter or a pipette. The 
pipette and rhinyle catheter deposited solution towards the rear of 
the nasal cavity at the site of the nasopharynx and sprays deposited 
droplets on the anterior side of the nasal cavity. Fifty percent of the 
drops from the pipette and rhinyle catheter were cleared in 14 and 
20 minutes whereas the 200µ 1 and 100µ l sprays were cleared in 
120 and 240 minutes. 
10 
f Environmental conditions such as the relative humidity and 
temperature, may also influence nasal clearance (Aoki et al., 1976; 
Hardy et al, 1985). 
It is well established that pathological conditions involving 
mucociliary dysfunction can greatly affect the clearance rates. For 
example, Kartagener's syndrome, Sjogren's syndrome, cystic fibrosis, 
and nasal polyposis have been shown to slow down the clearance 
rates (Hardy et al., 1985). The common cold can cause either rapid or 
slow clearance, depending on whether the subject has a 'runny nose' 
or nasal congestion (Bond et al., 1984). However, Phillpotts et al., 
(1984) reported that the rate at which human interferon-a was 
cleared from the nose was not substantially altered during a cold. 
Therefore, it seems likely that high concentration of interferon could 
be maintained in the nose during rhinovirus infection by means of an 
intranasal spray. 
1.4 Nasal Absorption of Peptides and Proteins -
Physicochemical Considerations 
There are various factors associated with peptide and proteins 
which affect their transport through the biological membranes. These 
include high molecular weight, concentration, volume of the dose 
administered to the nasal cavity and formulation composition. 
1.4.1 Effect of Molecular Weight: 
Proteins and peptides have poor bioavailability after intranasal 
administration because of their high molecular weight. Table 1 lists, 
in order of increasing molecular weight, the bioavailabilities of a 
1 I 
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Table 1. Intranasal bioauailabilities of proteins and peptidesa 
Compound Amino Acids Bioauailability 
(No.) (%) 
TRH 3 45 
Metkephamid 5 100 
Somatostatin analog 6 75 
OHytocin 9 1 
Oesmopressin 9 1 0 
-
Buserelin 9 2.5 N 
LH-RH 1 0 1.5 
Nafarelin 1 0 2 
ACTH analog 1 7 1 2 
Se cretin 27 1 0 
Glucagon 29 < 1 
Calcitonin 32 < 1 
GH - RH 40 < 1 
Insulin 51 < 1 
Beta-Interferon 165 < 1 
Growth hormone 1 9 1 < 1 
a Source: Lee, 1990. 
senes of peptides and proteins after intranasal administration (Lee 
1990). Data indicates that, for low molecular weight peptides such as 
thyroid-releasing hormone and metkephamid, bioavailability can be 
quite high after intranasal administration; but for larger peptides 
and proteins, the nasal mucosa is relatively impermeable. Very poor 
bioavailability was observed for drugs of molecular weight greater 
than 1000 daltons (McMartin et al., 1987). 
Maitani et al., ( 1989) investigated the nasal absorption of two 
dextran derivatives, fluorescein isothiocyanate - dextran (DT) and 
fluorescein isothiocyanate diethylamino ethyl dextran (DE) m the 
presence of sodium glycocholate to study the influence of molecular 
weight and charge using a rabbit model. The concentration of DT in 
plasma decreased as the molecular weight of DT was increased. The 
concentration of DE in plasma increased conversely with molecular 
weight of DE (<10000). When DE & DT of same molecular weight were 
given nasally, DE which carries a positively charged substituent 
showed higher plasma levels when compared to DT. 
1.4.2 Effect of Drug Concentration: 
It was observed that the nasal absorption of L-tyrosyl-L-
tyrosine was concentration dependent m the range of 2.8XI0-4 to 
2. 2X 10-3M (Huang et al., 1985). Harris (1989) reported that a greater 
response for desmopressin was observed after the 100 µ 1 dose than 
with the 200 µ l dose given in the spray form. Su et al. (1985) 
reported that the area under the curve of serum metkephamid levels 
versus time increased linearly with concentration. However, Aoki et 
al. (1976) reported that there was no significant effect on 
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( distribution and clearance from the nasal cavity when the 
concentration of human serum albumin was changed from 3 to 30%. 
1.4.3 Effect of Dose Volume: 
The volume that can be administered nasally is limited. If large 
volumes are administered, much of the preparation is likely to be 
swallowed at the time of dosing. Harris et al. ( 1988) studied the 
effect of dose volume on the nasal bioavailability of desmopressin. It 
was found that the bioavailability of intranasal desmopressin from 
2X50 µ L dose (20%) compared with 1X50 µ L (11 %) and lXlOO µL 
(9%) spray doses. This finding suggests that an optimal dosage is 
obtained by delivering drug once into each nostril. In another study 
(Harris, 1989), the same group reported that greater absorption of 
desmopressin was observed from 100 µ 1 than from 200 µ 1. 200 µ 1 
spray was cleared in 120 min compared to 240 min of clearance time 
for 100 µl spray. However, Aoki et al. (1976) reported that no 
significant difference was found when the volume was varied from 
0.1 to 0.75 ml. 
1.5 Pharmacokinetics of Nasal Absorption 
Pharmacokinetics may be simply described as the 
mathematical relationship that exists between the dose of a drug and 
the measurable concentration in a readily accessible site in the body 
(e.g., plasma or blood). The fundamental pharmacokinetic parameters 
of interest are clearance, volume of distribution, half-life and 
bioavailability. 
1 4 
( The principal pharmacokinetic rationale for employing the 
nasal route is to accommodate drugs that are extensively 
metabolized in the gut wall or that are subjected to extensive first-
pass elimination m the liver when administered orally. Another 
important reason is to provide a suitable route of administration for 
drugs such as peptides or proteins, which are destroyed by the 
gastrointestinal fluids, and not capable of adequate absorption into 
the systemic circulation following oral administration. 
1.5.1 Factors Affecting Nasal Absorption: 
Factors that could affect the pharmacokinetic parameters 
following intranasal administration are (Colaizzi, 1985): 
1. Physiology-related factors, such as 
a. Vascularity 
b. Speed of mucous flow 
c. Presence of infection 
d. Prevalent atmospheric conditions 
2. Dosage form-related factors, such as 
a. Concentration of drug 
b. Physicochemical properties of drug 
c. Density/viscosity of the formulation 
d. pH of the medium 
e. Pharmaceutical excipients used 
f. Biocompatibility: irritancy, toxicity, etc. 
3. Administration-related factors, such as 
a. Volume 
b. Droplet size 
1 5 
c. Spray characteristics 
d. Site of deposition 
e. Rate and extent of loss from the site of application 
Bioavailability is defined as the fraction of the unchanged drug 
reaching the site of drug action, or more usually the systemic 
circulation following administration by any route. The bioavailability 
of a drug after intranasal administration may be expressed in terms 
of absolute absorption, Ae, determined from the area under the 
curve (AUC) following the intravenous (i. v .) and intranasal (i.n.) dose 
(Colaizzi, 1985). 
A _ (AUC)i.n.(Dose)i.v. 
e - (AUC)i.v.(Dose)i .n. 
----- eq (1) 
where the AUC was extrapolated to an infinite time following the 
administration of a single intravenous or intranasal dose. 
Ae can also be calculated from the urinary excretion data 
following intravenous and intranasal administration of a single dose 
of drug. It is determined from the total amount of drug excreted in 
the urine in the unmetabolized form (Au00): 
Ae = (AU00)i.n.(Dose)i.v. 
(AU00)i. v.(Dose)i.n. 
----- eq (2) 
This equation 1s valid only when the fraction of drug dose absorbed 
and excreted in the urine is the same for both intravenous and 
intranasal routes. 
If the body is considered to act as a single compartment, the 
pharmacokinetic behavior of a drug administered by the intranasal 
route may be calculated according to the following model (Colaizzi, 
1985): 
XIN--absorption--->XB, V--elimination---> XE 
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where X1N represents the amount of drug administered to the nasal 
site, Xs represents the amount of drug in the central compartment, V 
is the apparent volume of distribution, and XE is the amount of drug 
eliminated. 
1.5.2 Zero-order Kinetics: 
In cases where the absorption of drugs from the nasal site of 
administration follows zero-order kinetics, e.g., controlled delivery, 
the plasma profile of the drug may be described by(Colaizzi, 1985) 
dXB =Ko - KeXB 
dt ----- eq (3) 
rn which Ko is the zero-order absorption rate constant, and Ke is the 
overall elimination rate constant. Then, the plasma concentration of 
drug may be expressed as 
Cp =Ko (1 - e-Ket) 
Cl ----- eq (4) 
where Cl is the total body clearance, and t represents any specified 
time interval following the drug administration. The plasma drug 
level following zero-order transnasal permeation of the drug would 
increase to a steady-state plateau level (CpS S) and then begin to 
decline exponentially after time tp , which is the time when there is 
no more absorption of the drug from the nasal cavity. 
1.5.3 First-order Kinetics: 
In cases where the absorption of drugs from the nasal site of 
administration follows first-order kinetics, the plasma profile of the 
drug can be described by (Colaizzi, 1985) 
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----- eq (5) 
where Ka is the first-order absorption rate constant, F is the fraction 
of applied dose absorbed, XrN is the amount of drug administered to 
the absorption site, Xs is the amount of drug in the central 
compartment, Ke is the overall elimination rate constant. Then, the 
plasma concentration of drug can be expressed as 
FXO K Cp = IN a (e-Ket _ e-Kat) 
V(Ka-Ke) 
----- eq (6) 
where XOrN is the initial drug dose applied to the site of absorption at 
the time zero. 
The nose is an interesting organ from kinetic point of view 
because, in addition to the process of drug release, absorption, and 
metabolism, it also has a carrier- and drug-translocating mechanism, 
namely mucociliary clearance. A mathematical model was developed 
by Gonda et al. (1990) to describe the rate processes involved in the 
deposition of drugs placed in their delivery systems into the human 
nasal cavity. The model contained first-order parallel and sequential 
irreversible rate processes representing the convective drug and 
carrier transport by fluid flow, mucociliary clearance and peristalsis, 
drug release and absorption, and decomposition of the drug prior to 
its appearance in the systemic circulation. The numerical values of 
the parameters used were based on literature data from clearance 
studies of nonabsorbable markers deposited in the human nasal 
cavity. Data obtained under a variety of experimental conditions 
were consistent with the model. The fitted values for DTPA 
(Diethylene Triamine Penta Acetic acid) powder formulation (Gonda 
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et al., 1990) were not consistent with the observed values. The effect 
of bioadhesive carriers was successfully simulated by reducing the 
mucociliary clearance rate constants for the transport from the the 
posterior part of the nose into the gastrointestinal tract. The 
simulation showed that bioadhesion improved bioavailability and 
reduced the variability in absorption which might be caused by a 
variable pattern of deposition in the nose. Variable bioavailability 
could result from removal of the drug from the nasal cavity by 
sniffing, blowing, or wiping the nose, leading to different drug 
residence times in the nose. The model simulations further suggested 
that drug decomposition in the nose, while lowering bioavailability, 
also reduced variable absorption due to variable residence times of 
the drug in the nose. 
The plasma concentration following intranasal administration 
shows a concentration profile that is similar to an intravenous bolus 
injection (Lau et al., 1989). The rate of nasal permeation is very 
rapid and it takes a very short period of time to reach the peak 
plasma level. Drugs with poor oral absorption (e.g. insulin, 
sulbenicillin, cephacetrile, phenol red and disodium cromoglycate) 
and drugs with extensive hepatic first-pass metabolism (e.g. 
progesterone, estradiol, testosterone, hydralazine, propranolol, 
cocaine and nitroglycerin) can be rapidly and completely absorbed 
through the nasal mucosa into the blood circulation (Chien et al., 
1989). 
1 9 
1.6 Enhancement of Nasal Absorption of Peptides and 
Proteins 
Peptides and proteins usually result in poor bioavailability 
when administered nasally. The obvious reason is their relatively 
large size and the impermeability of nasal membrane to these high 
molecular weight compounds. Other possible reasons for low 
bioavailability may be : (a) the high polarity of peptides and 
proteins, (b) absorption by a carrier-mediated mechanism, (c) 
hydrolysis m the nasal cavity, or (d) combinations of the above 
factors. 
Various approaches have been used to enhance the nasal 
absorption and systemic bioavailability for peptides and proteins as 
well as other drug molecules. 
1.6.1 Structural Modifications: 
The physicochemical properties of drugs can be altered by 
chemical modification. When administered nasally, the modified 
drugs may provide improved bioavailability. 
Huang et al. (l 985a), using L-tyrosine as a model amino acid, 
studied the effect of structural modification on its absorption. 
Acylation of the amino group on the L-tyrosine molecule had no 
effect on the lipophilicity or rate of nasal absorption of the amino 
acid. On the other hand, esterification of the phenolic and carboxyl 
groups resulted in derivatives which are more lipophilic than L-
tyrosine. The in-situ rates of nasal., absorption of the carboxylic acid 
esters were significantly greater than that of L-tyrosine, whereas the 
0-acyl esters were absorbed with rates similar to that of the original 
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ammo acid. It was suggested that the enhancement in the nasal 
absorption of the carboxylic acid esters of L-tyrosine might be the 
result of the masking of the negative charge that was on the 
carboxylate moiety. 
1.6.2 Formulation Design: 
The proper selection of pharmaceutical excipients m the 
development of nasal formulations could enhance the formulation 
stability and/or the nasal bioavailability of a drug. 
Harris et al. (1989) reported that the addition of methyl 
cellulose as a viscosity enhancing agent changed the pattern of 
deposition and clearance of intranasal desmopressin when 
administered by nasal spray and drops. The results showed that the 
addition of 0.25% w/v of methyl cellulose produced a more sustained 
and slower absorption. However, there was no increase in the total 
bioavailability. These results were consistent with the findings of 
Hussain et al. (1980) who, in a dog study, found that the addition of 
methyl cellulose to a nasal solution of propranolol produced a more 
sustained blood drug profile, but that the bioavailability was equal to 
a solution without the viscosity enhancer. Maitani et al. (1989) 
examined the effect of A vicel on the nasal absorption of Human 
interferon-B in rabbits from a powder dosage form. Avicel did not 
produce any significant effect on nasal absorption of Human 
interferon-B from this type of product. 
Nagai et al. ( 1984) studied the effect of lactose, microcrystalline 
cellulose, hydroxypropyl cellulose and carbopol-sodium in powder 
dosage forms for delivering insulin to the nasal cavity. The 
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absorption of insulin was fastest with microcrystalline cellulose and 
was sustained when carbopol-sodium was used in the preparation. 
High enhancement was observed when insulin and carbopol were 
freeze-dried together prior to administration. The final powder 
dosage form produced a hypoglycemia of one third of that observed 
by intravenous injection assuming that the same dose of insulin was 
administered. 
1.6.3 Membrane Permeation Enhancers: 
The concept of adding a component to a therapeutic drug 
formulation to increase absorption and the possible mechanisms 
involved has been explored extensively for transdermal delivery. 
Little information is known of the physico-biochemical nature of the 
nasal mucosal membrane and its influence on peptide transport. The 
extent of systemic transport for a given peptide that results from 
energy dependent active transport processes, versus passive 
transport, is unknown and may vary given the size of the molecule, 
its partition coefficient, charge characteristics and its susceptibility to 
proteolysis by mucosal membranes. Various chemical components 
have been used in an attempt to increase the uptake of proteins and 
peptides through the nasal mucosa (Chien et al., 1989; Lee 1990). 
These include the use of surfactants, bioadhesive agents and 
vasoactive agents to promote nasal absorption. 
1.6.3.1 Surface Active Agents: 
The effect of surfactants on drug absorption has been the 
objective of many studies. A number of these were reviewed by 
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Gibaldi (1970), Gibaldi and Feldman (1970) and Lee (1990). A wide 
variety of ionic and nonionic surfactants such as hydrophobic bile 
salt derivatives (deoxycholate, cholate, chenodeoxycholate, 
glycocholate), fusidic acid derivatives, sodium lauryl sulfate, 
potassium laurate, saponin and various ether and ester derivatives of 
polyoxyethylene have been shown to increase the nasal absorption of 
macromolecules such as insulin (Hirai et al., 1978, 198la, 8lb, 8lc; 
Pontiroli et al., 1982), calcitonin (Sandow et al., 1985), thymopentin 
(Audhya et al., 1983), vasopressin (Harris et al., 1989), leutinizing 
hormone releasing hormone (Fink et al., 1974 ), enkephalins (Su et al., 
1985) and human growth hormone (Baldwin et al., 1990). 
Hirai et al. (1978) studied the effect of surfactants such as 
saponin, sodium glycocholate and polyoxyethylene-9-lauryl ether on 
nasal absorption of insulin in dogs. Insulin in the absence of the 
surfactant produced slight hypoglycemia whereas the presence of 
only 1 % surfactant enhanced uptake of insulin. The blood glucose 
level in dogs was reduced by 25-100% within 1-2 hours after 
intranasal administration. Sodium glycocholate produced the 
maximum effect followed by polyoxyethylene-9-lauryl ether and 
saponin. The results indicated that the alteration of the nasal mucosa 
by surfactants increases the permeability of mucous membrane, 
which leads to enhancement in the nasal absorption of insulin. 
Coadministration of insulin with 1 % surfactant (such as the surfactant 
of nonionic ether type, anionic or amphoteric-type, bile sats, saponin, 
and surfactin) in rats was noted to produce a reduction in blood 
glucose levels (Hirai et al., 198 la). The results suggested that 
surfactants with an HLB value of 8-14 yield a greater reduction of 
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blood glucose leve ls. It was hypothesized that the surfactant 
molecule increases nasal permeability or reduces the proteolytic 
enzyme activity in the nasal mucosa, and therefore promotes the 
nasal absorption of insulin. It was noted that polyoxyethylene-9-
lauryl ether produced a maximum hemolytic and protein-releasing 
effect on the biomembrane, whereas it yielded only a slight 
inhibition of the enzymatic degradation of insulin (Hirai et al., 
1981 b). On the contrary, sodium glycocholate produced a lesser 
extent of both hemolytic and protein-releasing effects, but it showed 
a significant inhibition of the leucine aminopeptidase activity. 
Moses et al. (1983) studied the efficacy and reproducibility of 
insulin given nasally to normal and diabetic subjects from an insulin-
deoxycholate (1 % w/v) aerosol. The formulation resulted in peak 
serum insulin concentrations within 10 minutes after nasal 
administration. The blood glucose level began to fall within 10 
minutes and reached the nadir level of 54% after 30 minutes. The 
nasal absorption of insulin was approximated to be 10-20% as 
efficient as intravenous administration. When compared to normals, 
the insulin effect was prolonged for 5 hours in both type I and type 
II diabetics although the mechanism was not clear. 
In an extensive study, Gordon et al. (1985), using 40 healthy 
volunteers, compared the ability of eight different bile salts 
(ursodeoxycholate, chenodeoxycholate, cholate, taurocholate, 
glycocholate, deoxycholate, taurodeoxycholate and 
glycodeoxycholate) to enhance insulin absorption after nasal 
administration. The effectiveness of the individual bile salt was 
positively correlated to the hydrophobicity of the steroid nucleus, as 
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homogenates was maximally enhanced by sodium glycocholate. 
However, the observed bioavailability was only 3% of as that of an 
L v. administered dose. 
Mishima et al. (1987) investigated the inhibitory action of 
various enhancers such as sodium caprylate, sodium caprate, sodium 
laurate, sodium glycocholate on aminopeptidase activity in rats and 
rabbits. It was found that sodium laurate (98%) showed the highest 
inhibition of aminopeptidase activity in rat homogenate, followed by 
sodium glycocholate (79%), sodium caprate (74%) and sodium 
caprylate (70%). In a rabbit homogenate, sodium caprate showed 89% 
inhibitory action followed by sodium caprylate (88% ), sodium laurate 
(87%) and sodium glycocholate (86% ). 
Aungst et al. ( 1988) compared the efficiency of the nasal, 
rectal, and buccal routes for delivering insulin to rats using sodium 
glycocholate as an enhancer. A five percent concentration of sodium 
glycocholate was found to significantly increase insulin efficacy by 
each route. The rank order was nasal > rectal > buccal > sublingual. 
Nasal and rectal insulin were roughly half as effective as 
intramuscular insulin. 
Tengamnuay and Mitra (1990) used mixed micelles of fatty 
acids and bile salt to optimize the penetration efficacy while 
m1mm1zmg any changes in membrane integrity caused by 
permeation enhancers. Using in situ nasal perfusion technique, they 
found that mixed micelles of sodium glycocholate and various fatty 
acids m a 15:5 mM ratio were much more effective in enhancing the 
nasal absorption of dipeptide [D-Arg2]Kyotorphin than the individual 
adjuvants. The adjuvant activity of the mixed micelles was increased 
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( by increasing the ionic strength of the perfu sate and affected by the 
structure of the lipid component. Oleic acid , a cis-unsaturated fatty 
acid, was more effective than elaidic acid, the trans-isomer, whereas 
cis-linoleic acid and trans-linolelaidic acid were equally effective. 
Mixed micelles appeared to cause transient changes in the integrity 
of the nasal mucosa that were fully reversible within 20-40 min 
after a 60 minute exposure as judged by return of the mucosa to its 
original impermeable state. 
A fusidic acid derivative, sodium tauro-24,25-dihydrofusidate 
(STDHF) seems to be the most promising enhancer for use in 
increasing the absorption of nasally administered peptides and 
proteins (Lee, 1990). Longenecker et al. (1987) reported that STDHF 
enhanced insulin absorption in the sheep model when insulin was 
delivered as nasal drops. The observed bioavailability after nasal 
delivery was 16.4% relative to i.v. administration. The concentration 
of STDHF and the ratio of STDHF to insulin were critical parameters m 
increasing the absorption of insulin. These observations were 
consistent with Hirai et al. (1981 ), who reported that enhanced 
serum insulin values can be observed only when bile salts exceed the 
CMC. The optimum ratio of STDHF to insulin was found to be between 
5 and 10 at STD HF concentrations greater than its CMC (0.16% ). 
Optimum absorption was observed at a concentration of 0.3% (w/v) 
of STDHF. 
In another study, Verhoef et al (1989) reported the promoting 
ability of STDHF on nasal absorption of insulin in rats and rabbits. 
The identical fusidate formulations enhanced insulin bioavailability 
from 0.9% to 5.2% in rabbits and from 0.3 % to 18% in rats. Co-
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( administration of STDHF with the trypsin inhibitor aprotinin resulted 
10 an increase in insulin bioavailability in rats and a decrease 10 case 
of rabbits. These results indicate that there seems to be significant 
interspecies differences which can not be overlooked. Baldwin et al. 
(1990) reported the nasal absorption of human growth hormone 10 
three animal models. Formulations were nasally administered using a 
Hamilton syringe with a polyethylene tubing (PE 10) attached. In rats, 
when hGH with 0.5% STDHF was administered in an 80-J.11 dose 
volume via the nasopharyngeal route, the bioavailability was 32%. 
Administration of same formulation directly into the nasal cavity 
through the nares 10 a volume of 20µ l resulted in bioavailability of 
17.2% (relative to i.v.). The presence of 0.5% STDHF caused an 11-
fold increase in bioavailability of hGH in rats and in rabbits and a 21-
fold increase in sheep. In all three species, the pharmacokinetic 
profile observed, following nasal administration, was a pulsatile 
profile. That is, the absorption of hG H was rapid followed by rapid 
clearance of hGH. Glycocholate or taurocholate at 0.5% was 3 to 5 
times less effective than STDHF in enhancing hGH absorption in rats. 
The nasal absorption of hGH decreased as the concentration of STDHF 
was reduced from 0.3 to 1.0% w/v. 
Hermen et al. (1989) investigated the utility of dimethyl-beta-
cyclodextrin in enhancing the nasal absorption of 17 beta-estradiol 10 
rabbits and rats. High bioavailabilities of estradiol were observed 
both in rabbits (95%) and rats (67%) when complexed with 
cyclodextrin. In another study (Pontiroli et al., 1990), glucagon was 
complexed with cyclodextrin to increase solubility and delivered 
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nasally to normal volunteers. Results showed that there was no 
significant in plasma glucagon levels. 
A number of mechanisms have been hypothesized to explain 
the activity of nasal membrane permeation enhancers (Lee et al., 
1988). For peptides and proteins that tend to aggregate in solution 
(for example, insulin), solubilization of the monomeric species will 
increase the molecule's thermodynamic activity and therefore its 
transport across the membrane. Bile salts and STDHF have been 
shown to inhibit protease activity and enhance the absorption of 
drug molecules. Formation of transient hydrophillic pores in the 
membrane bilayer by the bile salts also has been proposed as a 
potential mechanism for enhanced protein absorption (Gordon et al., 
1985). This mechanism, however, does not explain how, once m the 
cytoplasm of the epithelial cell, the protein or peptide would be 
transported out the basal side of the cell and into the capillary bed. 
Surfactants such as polyoxyethylene-9-lauryl ether have been 
observed to enhance nasal absorption by eroding the nasal mucous 
membrane. Specific enhancers such as STDHF seem to loosen the tight 
cellular junctions and promote the nasal absorption of proteins and 
peptides. 
Though the presence of an enhancer usually improves the 
uptake of peptides and proteins by the nasal membrane, major 
concerns regarding the toxic effects and nasal membrane irritation 
upon administration for long periods remain unaddressed (Martin et 
al., 1978, 1981). Duchateau et al. (1986) reported that the 
ciliotoxicity of the bile salts increased with increasing 
hydrophobicity. Dihydroxy bile salts are more toxic than trihydroxy 
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bile salts. Deoxycholate was found to be extremely ciliotoxic at a 
concentration of 5 mM/l. STDHF seems to be less toxic and less 
irritating than bile salts (Lee et al., 1988). An ideal enhancer which 
does not disrupt normal nasal functions and can enhance the uptake 
of peptides and proteins through the nasal membrane has yet to be 
found. 
1.6.3.2 Bioadhesive Agents: 
In addition to the penetration and enzymatic barriers, rapid 
clearance of the administered dose from the site of administration 1s 
another hurdle limiting the absorption of peptide and protein drugs 
from the nasal cavity. Nasally administered drugs are usually cleared 
from from the site of deposition within 30 minutes. It is postulated 
that by increasing the residence time of drug in the nasal cavity, 
absorption would be increased since more time will be available for 
drug to be absorbed. Residence time can be increased by 
coadministering or formulating a number of different agents into the 
nasal products. 
Morimoto et al. (1985) demonstrated the nasal absorption 
promoting activity for the bioadhesive agent, polyacrylic acid. Using 
a rat model, polyacrylic acid gel was shown to enhance the biological 
actions of insulin and calcitonin, both of which were inactive when 
administered alone. Formulation pH ( 4.5-7 .5) did not appear to affect 
insulin absorption from the gel formulation, however low viscosity 
gels demonstrated a more rapid onset of insulin activity, as 
measured by hypoglycemic response. However, the nasal 
administration of insulin in 1 % w/v carboxymethyl cellulose solution 
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( had no hypoglycemic effect. Harris et al. (1989) reported that the 
addition of 0.25% w/v of methyl cellulose produced a more sustained 
and slower absorption of desmopressin. However, there was no 
increase m the total bioavailability which was consistent with the 
findings of Hussain et al. (1980) who, in a dog study, found that the 
addition of methyl cellulose to a nasal solution of propranolol 
produced a more sustained blood levels of drug. Thus, these results 
suggest that addition of a viscosity builder may sustain drug 
absorption rather than increasing the bioavailability. 
A similar approach involves the delivery of solid peptide 
formulations designed to absorb water and to gel upon contact with 
the mucosa. Good bioavailability of insulin (30%) was observed when 
insulin was freeze dried together with carbopol 934 prior to nasal 
administration to dogs (Nagai et al., 1984, 86). Illum et al. (1987) 
studied three bioadhesive microsphere systems (albumin, starch-
spherex and DEAE-dextran) for nasal administration. The half life of 
clearance for starch microspheres was found to be in the order of 
240 minutes as compared to 15 minutes for the liquid and powder 
formulations. In another study, the same group (Ilium et al., 1988) 
reported that incorporation of an absorption enhancer, lysolecithin 
into the starch microspheres resulted in increased uptake of 
gentamicin in rats and sheep. The observed bioavailability was 50% 
of the i. v. dose as compared to less than 1 % for a simple nasal 
solution of gentamicin. Bjork et al. (1988) investigated degradable 
starch microspheres as a nasal delivery system for insulin in rats. 
Insulin (0.75U/kg and 1.7U/kg) - starch microspheres administered 
as a dry powder resulted in a dose-dependent decrease in blood 
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f glucose and a concomitant rncrease 10 serum insulin. Blood glucose 
was reduced within 30-40 min by 40% and 64% respectively using 
the two aforementioned doses. The insulin peak was reached 8 
minutes after dosing and the observed bioavailability was 30%. 
1.7.3.3 Vasoactive Drugs: 
Olanoff and co-workers (1987) investigated a third approach to 
enhance peptide delivery using what they term 'physiological 
modifying agents'. These agents have vasoactive properties and exert 
their action by increasing nasal mucosal blood flow. In theory, by 
increasing nasal blood flow, concentrations of drug on basal side of 
the nasal mucosa! membrane would remain low, increasing the 
effective concentration gradient, thereby augmenting peptide 
permeation across the mucosa! membrane by passive diffusion. 
Agents capable of increasing nasal blood flow include histamine, 
leukotriene D4, prostaglandin Ei and the beta adrenergic agonists, 
isoprenaline and terbutaline. Also included in this group are agents 
which promote the release of endogenous vasoactive substances such 
as histamine, kinins, prostaglandins, and the vasoactive peptides. In 
a clinical trial with eight normal subjects, the intranasal 
administration of histamine immediately prior to desmopressin 
administration increased the antidiuretic response. These results and 
additional data showing an increase in nasal blood flow in the 
presence of histamine suggest that peptide absorption is in part 
limited by blood flow . 
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( 1.7 Animal Models Used m Evaluation of Nasal Absorption 
Studies 
Review of literature has shown that there are two types of 
models which are used for evaluation of nasal absorption. 
1. 7.1 In Situ Absorption Models: 
In-situ nasal perfusion studies can be used to evaluate the 
nasal absorption potential of a drug and to predict the in vivo rate of 
absorption. The surgical perfusion procedure was originally 
developed by Hirai et al. ( 1981 a) using the rat as animal model. The 
experimental set up is given in Figure 2. 
In this model the rat is anesthetized and an mc1s10n is made in 
the neck. The trachea is then cannulated with a polyethylene tube 
and another tube is inserted through the esophagus towards the 
posterior part of the nasal cavity. The nasopalatine tract which 
connects the nasal cavity with the mouth is sealed with an adhesive 
to prevent the drainage of the drug solution from the nasal cavity 
into the mouth. The drug solution is placed in a reservoir vessel and 
circulated through the nasal cavity via a peristalic pump. After 
flowing through the nasal cavity, the perfusion solution passes out of 
the nostrils, flows through the funnel, and returns to the reservoir 
again. The extent and the rate of nasal absorption are determined, 
over a period of time, by analyzing the drug concentration remaining 
in the perfusing solution. 
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drug reservoir _ ___.._....__ 
magnetic stirring bar 
Figure 2. The experimental setup for m situ perfusion technique m 
rat model. 
Source: Chien et al., 1989. 
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1.7.2 In Vivo Absorption Models: 
As shown in Figure 3, the surgical procedure for in vivo studies 
rn rats is similar to that described for the in-situ nasal perfusion 
studies. The drug solution is administered to the nasal cavity through 
the esophageal cannulation tubing or into the nostril with a syringe. 
The extent and the rate of nasal absorption are determined by 
analyzing drug concentrations in the plasma or in the urine over a 
period of time. Since all the possible outlets in the in vivo rat model 
are blocked after surgical preparation, the only possible passage for 
the absorption of a drug into the systemic circulation is penetration 
through the nasal mucosa. This approach is considered to provide a 
well controlled animal model for screening the nasal absorption 
potential of drug candidates. 
A number of different animal species have been studied to 
evaluate nasal absorption. These include the rat, guinea pig, rabbit, 
dog, sheep, and monkey. Among these animal models, the rat model 
has been used extensively for evaluation of the nasal absorption of 
various drugs such as propranolol (Hussain et al., 1979; 1980); 
naloxone and buprenorphine (Hussain et al., 1984 ); sulbenicillin, 
cefazolin, cephacetrile, phenol red, salicylic acid, aminopyrin, and 
bucolome (Hirai et al., 1981 a); insulin (Hirai et al., 1981b,198 lc; 
Morimoto et al., 1985; Deurloo et al., 1989); enkephalins (Su et al., 
1985); cyclo-(-Pro-Phe-D-Trp-Lys-Thr-Phe); horseradish peroxidase 
(McMartin et al., 1987) and calcitonin (Morimoto et al., 1985). Drugs 
studied nasally using the rabbit as an animal model include 
progesterone and its hydroxy derivatives (Corbo et al., 1988), insulin 
(Zia et al., 1989; Deurloo et al., 1989) and human interferon-beta 
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Figure 3. The top and side views of the cannulation arrangement for 
in vivo studies in rats. 
Source: Chien et al., 1989. 
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(Maitani et al., 1989). Audhya et al. (1983) used the guinea pig as an 
animal model to determine the efficacy of thymopentin following 
administration by various routes. The in vivo dog model was used to 
evaluate nasal absorption of propranolol (Hussain et al., 1980) and 
insulin (Hirai et al., 1978; Nagai et al., 1984; Longnecker et al., 1987; 
Farraj et al., 1990). Sheep were used as an animal model for various 
drugs such as insulin (Longenecker et al., 1987). The monkey has 
been used to evaluate the nasal absorption of progesterone (Anand 
Kumar et al., 1982), B-Endorphin (Jagannadha Rao et al., 186), insulin 
(Anik et al., 1984 ), nafarelin acetate (Anik et al., 1984) etc. 
The rat model is the most widely used model for evaluation of 
the nasal absorption potential of different drug molecules because 
the rat is a small animal with low cost, is easy to handle and is 
inexpensive to maintain. However, the small nasal cavity and nostrils 
of the rat restrict the evaluation of formulations such as metered 
sprays, powders and microspheres. Because of their larger nostrils 
and body size as compared to rat model; the dog, sheep and monkey 
models are more suitable and practical for evaluating wider variety 
of formulations and modes of administration. These animals are 
larger in size, more difficult to handle, and more expensive to 
maintain in the laboratory. The rabbit offers certain advantages as 
an animal model. It is a laboratory animal as commonly accessible as 
the rat, and provides large nostrils and increased nasal surface area 
that is comparable to that of human beings. The rabbit is relatively 
inexpensive, readily available, and easily maintained in the 
laboratory setting. However, the nonsurvival and surgical nature of 
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the perfusion technique (Hirai et al., 198 1 a) restrict the use of this 
approach in these species. 
Mehta et al. ( 1990) developed a nonsurgical perfusion 
technique and presented preliminary data using rabbit as animal 
model. However more studies are necessary to establish and validate 
this technique. 
1. 7.3 Physical and Chemical Parameters to be Considered in 
Evaluation of Absorption Models 
1. 7.3.1 Effect of Perfusion Rate: 
Huang et al. ( 1985) examined the effect of perfusion rate on 
nasal absorption using the in situ nasal perfusion technique in rats. 
As the perfusion rate was increased from 1.0 to 2.5 ml/min, the rate 
of nasal absorption of phenobarbital increased initially and then 
reached a plateau at 2 ml/min and was independent of the rate of 
perfusion when pumped faster than 2 ml/min. 
1.7.3.2 Effect of Perfusate Volume: 
The effect of varying the volume of the perfusion solution on 
the apparent rate of absorption was studied using phenobarbital, L-
tyrosine, propranolol and phenol red (Huang et al., 1985). The 
apparent absorption rate constants were increased when the volume 
of perfusate was increased from 3 to 20 ml. The dependency of 
absorption rate constants on volume can be mathematically 
described in accordance with Fick's law of diffusion: 
d m Vdc dC 
= =-DA ------ eq (7) 
dt dt dx 
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where m = amount of the drug in the perfusion solution 
v = volume of the solution 
dC/dx = Concentration gradient across the nasal 
membrane with a thickness of h 
D = diffusion coefficient 
A = surface area of the nasal mucosa. 
1.7.3.3 Effect of pH: 
Hirai et al. (1978) reported that the extent and duration of 
hypoglycemia induced by the nasal application of insulin depended 
on the pH of the preparation. Absorption of insulin from the nasal 
mucosa was enhanced significantly when it was dissolved in an acid 
medium (pH 3.1) than in a neutral one. Similarly, the effect of pH on 
the nasal absorption of benzoic acid (pKa=4.19) was studied by 
Huang et al. (1985). As the pH of the solution was increased from 2 
to 7.19, the amount absorbed was decreased from 44% to 13% (Hirai 
et al., 1981). But Hussain et al. (1989) reported that the absorption of 
L-tyrosine was pH independent in the range of 4-7.4. 
1. 7.3.4 Effect of Partition Coefficient: 
The rate and extent of absorption of a drug through a biological 
membrane is influenced by its lipophilicity. Hussein et al. (1985) 
studied the effect of lipophilicity on the extent of nasal absorption of 
a series of barbiturates at pH 6.0, where the barbiturates (pKa=7 .6) 
exist entirely in their unionized form. A forty-fold difference in the 
partition coefficient of pentobarbital and barbital resulted only in a 
four-fold mcrease in the extent of absorption. Further more, it was 
also observed that the nasal absorption of L-tyrosine (Hussein., 
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1989) was not significantly changed when the partition coefficient 
was increased 50 times. Corbo et al. (1988) studied the nasal 
delivery of progestational steroids in overiectomized rabbits. It was 
found that octanol/water partition coefficient does not reflect the 
partition behavior of progesterone and its derivatives in the nasal 
mucosa. The systemic bioavailability was correlated well with the 
nasal mucosa/buffer partition coefficient. In another study (Corbo et 
al., 1990), the same group reported that nasal membrane 
permeability decreased as the order of hydrophilicity of the 
progestins increased. 
1.8 Insulin as Model Drug 
The first known description of diabetes is rn the Ebers Papyrus 
of 1500 BC. An effective treatment for diabetic patients came much 
later after insulin was discovered in 1921 by Banting and Best (Chien 
et al., 1989a). 
Diabetes is an enormous health and economic burden in the 
United States and the developed countries. As of 1985, the NIH 
estimated that more than six million residents of the United States 
had been diagnosed with diabetes, and an additional four million 
were thought to be undiagnosed. By the end of this century, the 
disease could affect 20 million people in the United States alone, 
where it is now responsible for about 40,000 deaths per year 
(Tzagournis et al., 1989). 
Insulin is a proteinous macromolecule composed of 51 ammo 
acids with a molecular weight of 5,808 daltons (Figure 4). Though 
insulin was discovered in 1921, it is still routinely administered in 
the form of an injection. However, the use of injections throughout 
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the life of a diabetic patient presents various problems including 
physical and psychic pain, hypertrophy or atrophy of the 
subcutaneous fat at an injection site and occasionally an allergic 
reaction throughout the whole body. A tremendous amount of effort 
has been directed towards developing new means of insulin delivery, 
including the recent efforts to develop self-regulating insulin 
delivery systems (Touitou et al., 1980; Ishida et al., 1981; Nagai et al., 
1986; Bjork et al., 1988; Farraj et al., 1990; Damge et al., 1990). 
Several of these attempts were started and have either ended or are 
continuing as laboratory research, with no products reaching the 
market. In a recent review, Chien et al. (l 989a) discussed the vanous 
approaches that have been developed for achieving systemic 
delivery of insulin. 
The choice of delivery routes is restricted by the molecular 
dimensions of insulin and its inherent instability as a protein 
molecule. Among the noninvasive routes, the nasal route seems to be 
a promising alternative to injection. Attempts to deliver insulin 
nasally dates back to 1922 when Woodyatt attempted to administer 
insulin unsuccessfully (Chien et al., 1989a). Since then many 
attempts have been made to deliver insulin nasally using a variety of 
animal models. When administered alone, the bioavailability of 
insulin has been found to be less than one percent because of its high 
molecular weight and its susceptibility to proteolytic degradation. 
When given with an enhancer or using the approaches described 
above, the observed bioavailability has been increased to as high as 
10-30%. 
4 1 
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Figure 4. The structure of insulin molecule. 
Source: Chien et al. , 1989a. 
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( Insulin was chosen as model drug for this work because it is a 
well researched polypeptide, a lot of data is available in the 
literature which can be served as a comparative data base for these 
efforts. 
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2. 0 BJECTIVES 
The rich vascularity and location of the nose make it an 
attractive site for the systemic absorption of drugs . Lipophilic drugs 
such as propranolol (Hussain et al., 1979), progesterone (Ananda 
Kumar et al., 1982), 17 JJ -estradiol (Hermens et al., 1990) etc, result 
in rapid and complete absorption after intranasal administration. 
Peptides and proteins, on the other hand are poorly absorbed 
nasally. The bioavailability of insulin in the absence of an enhancer 
was reported to be less than 1 % (Hirai et al., 1978, 1981 b, 198 lc). 
Similarly, the nasal bioavailability of nafarelin acetate in monkeys 
was found to be only 1 % of that from the intravenous administration. 
While the tripeptide, L-pyro-2-2aminodipyl-L-histidyl-L-
thiazolidine-4-carboxamide, although possessing fewer amino acids 
than insulin and nafarelin acetate, has a poor bioavailability of 7% 
(Hussain, 1985). It appears that the mechanism for nasal absorption 
of drugs, especially peptides and proteins, is not fully understood. In 
order to gain insight into the mechanism of nasal absorption, only 
few animal models have been developed and characterized, in spite 
of the great potential offered by the nasal route for systemic drug 
administration. Most of the mechanistic and absorption screening 
studies have been performed using the in-situ rat nasal recirculation 
technique (Hirai et al., 1981a). While this technique is convenient 
and reliable for in-situ studies for some drugs, it is not suitable for 
in-vivo screening of formulations intended for administration by 
spray devices which is the most popular means of nasal 
administration. The small nasal cavity and nostrils of the rat restrict 
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the evaluation of nasal formulations such as metered sprays, 
powders and microspheres in this model. 
Deurloo et al. ( 1989) observed significant interspecies 
differences m rats and rabbits using identical nasal formulations. 
STDHF at 1 % (w/v) enhanced nasal insulin bioavailability from 0.9 to 
5.2% and from 0.3 to 18.0% in rabbits and rats respectively. 
Coadministration with the trypsin inhibitor aprotinin increased 
insulin bioavailability in rats and decreased bioavailability in rabbits. 
In sheep model, the observed insulin bioavailability was 16.4% 
(Longenecker et al., 1987) . Baldwin et al. (1990), reported that the 
presence of 0.5% STDHF enhanced nasal absorption of hGH by 11-fold 
in rats and in rabbits and by 21-fold in sheep. Similarly, nasal 
administration of leuprolide acetate in rats resulted in a 
bioavailability of 6.0 to 40.0% when compared to 1. v. administration 
(Adjei, 1990). Intra-animal coefficient of variation of the data was 30 
to 60%. The same drug when administered nasally by spray to 
humans resulted in a mere 2% bioavailability. Hirai et al. (1981, 81a, 
81 b) reported that in a dog study, the nasal absorption of insulin was 
enhanced when it was dissolved in acid medium resulting in a 
bioavailability of 25% compared with the hypoglycemic effect 
following i.v. injection. However, in a human clinical study, the same 
insulin solution did not produce any hypoglycemic effect and similar 
results were observed with the rat model. These studies indicate that 
the absorption process of macromolecules through the biological 
membranes is not fully understood. Significant interspecies 
differences seem to exist and no suitable perfusion technique is 
available to evaluate these differences . The surgical, nonsurvival 
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nature of the rat recirculation technique limits its application only to 
rats due to economic reasons and thus these animals can not act as 
their own controls. Hence there is a need to develop perfusion 
techniques in large laboratory animals which can give better 
representation of the nasal mucosal absorption processes in human 
beings. Evaluation and validation of the non-surgical perfusion 
technique may address these problems. 
The objectives of this study were: 
(1) to develop and establish a non-surgical perfusion technique for 
use with large laboratory animals 
(2) to compare the new technique with the existing perfusion 
techniques 
(3) to identify the study conditions to establish and validate animal 
model 
(4) to evaluate various nasal formulations and/or modes of 
administration such as sprays, microparticles using the same model 
and compare with the perfusion studies. 
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( 3. MATERIALS AND METHODS 
3.1 Materials and Equipment: 
3.1.lMaterials: 
Acepromazine maleate, lot# 3890769 
Aveco Co., Inc., Fort Dodge, Iowa 50501 
Acetone, lot# 881807 
Fisher Scientific, Fair Lawn, NJ 07410 
Bovine insulin (25.7 I.U./mg) lot# 79F-0092 
Sigma Chemical Company, St. Louis, MO 63178 
Chemstrip bG test strips lot# 252169, 
Boehringer Mannheim Diagnostics, Indianapolis, IN 
Cotton balls, lot# 021399, 
Consumer Value stores, Woonsocket, RI 02895 
Dextrose injection (5% w/v), USP, lot# 33864JT 
Abbott laboratories, North Chicago, IL 60064 
Ethyl alcohol-200 proof, lot# 1094, 
U.S. Industrial Chemicals, Tuscola, IL 61953 
Fusidic acid sodium salt, lot# 48F-0204 
Sigma Chemical Company, St. Louis, MO 63178 
Glucose controls lot# 30843 
Boehringer Mannheim Diagnostics, Indianapolis, IN 
Hydrochloric acid, lot# 026490 
E.I. Dupont de Nemours & Co. (Inc.), Delaware 
Ketamine hydrochloride, lot# 440105 
Aveco Co., Inc., Fort Dodge, Iowa 50501 
Lancets, lot# 226396, 
Ulster Scientific, Inc., Highland, NY 12528 
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Maltose, lot# 19F-053 l 
Sigma Chemical Company, St. Louis, MO 63178 
Needles, lot# Wl 1587 
Becton Dickinson & Co., Rutherford, NJ 07070 
Olive oil, lot# 40H-01232 
Sigma Diagnostics, St. Louis, MO 63178 
Palmitic acid, lot# 59F-5601 
Sigma Chemical Company, St. Louis, MO 63178 
Poly(acrylic acid), lot# B570080 
BFGoodrich Company, Brecksville, OH 44141 
Polyethylene tubing, Intramedic, PE 240, PE 260 
Fisher Scientific, Fair Lawn, NJ 07410 
Potassium phosphate monobasic, lot# KHTC 
Mallinckrodt, Inc., Paris, Kentucky 40361 
Silicone ear plug, lot# SB-30100 
Santa Barbara Medco, Inc., Santa Barbara, CA 93160 
Skin gel, lot# 5Kl42B, 
Hollister Inc., Libertyville, IL 600048 
Sodium chloride, lot# 891067 
Fisher Scientific, Fair Lawn, NJ 07410 
Sodium hydroxide, lot# 880519 
Fisher Scientific, Fair Lawn, NJ 07410 
Sodium pentobarbital, lot# 26807 AF 
Abbott Laboratories, North Chicago, IL 60064 
Sodium phosphate dibasic, lot# 871003, 
Fisher Scientific, Fair Lawn, NJ 07410 
Sodium taurocholate, lot# l l 8F-5008 
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( Sigma Chemical Company, St. Louis, MO 63178 
3.1.2 Animals used: 
New Zealand White male rabbits, 3-5.5 kg 
Millbrook farm, Amherst, MA 01004 
3.1.3 Equipment: 
Accu-Chek II blood glucose monitor, Model 792 
Boehringer Mannheim Diagnostics, Indianapolis, IN 
AutoclixTM 
Bio-Dynamics, W. Germany 
Constant speed and torque control unit 
Cole-parmer Instrument Company, Chicago, IL 
Duo Seal Vacuum pump 
The Welch Scientific Company, Skokie, IL 
Freeze dryer, Model 77500 
Labconco Corporation, Kansas City, MO 64132 
Heating mantle 
Glas-Col Apparatus Co., Terre haute, IN 47802 
Infusion pump, model 352 
Orion research Inc. 
Magnetic Stirrer, model 417 
Electronic Laboratory equipment, Kansas City, MI 
Mettler analytical balance, AE240 Dual range balance 
Mettler Instrument Corporation, Highstown, NJ 
Motomatic + Motor generator 
Electro-craft Corporation , Hopkins, Minnesota 
pH meter 
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Markson Science, Inc., Del Mar CA 
POWER ST A TR variable autotransformer, 
The Superior Electric Co., Bristol, Con. 
Sartorius weighing balance, Model 1601MP8 
Sartorius GMBH, Gottingen, Germany 
Spray pump, 50 µl 
Pfeiffer metered dosage systems, Princeton, NJ. 
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3.2.0 Methods 
3.2.1 Original Non-Surgical Perfusion Technique (Old 
Method): 
Each rabbit was anesthetized using an intramuscular injection 
of 75 mg/kg ketamine hydrochloride, 7 .5 mg/kg acepromazine 
maleate and 12 mg/kg xylazine hydrochloride. A supplemental dose 
of 50 mg of ketamine hydrochloride and 5 mg of acepromazrne 
maleate was administered intraperitonially at the 60 minute interval 
to maintain the anesthesia when the experiment was extended. The 
original non-surgical perfusion technique was carried out according 
to the method of Mehta et al. (1990). After placing the animal on its 
back, a hard polyethylene tube was inserted by mouth into the 
trachea to allow breathing during perfusion of the nasal cavity with 
drug solution. A peroral nasal intubation cannula was prepared by 
connecting two pieces of hard polyethylene tubing with a soft 
polyethylene tube and folded in a shape suitable for insertion into 
the nasal cavity from the mouth. Figure 5 shows this cannula and the 
technique used for peroral nasal cannulation. The cannula was 
inserted in the mouth and pushed into the esophagus, approximately 
6 inches, and then pulled back carefully until the short end of the 
cannula reached into the nasal cavity. The long end of the cannula 
coming out of the mouth was connected to a perfusion pump. The 
placement of the cannula was tested by infusing a small amount of 
saline solution through the nasal cannula and observing saline flow 
from the nostrils. Twenty ml of insulin solution was perfused at a 
rate of 10 ml/hr and the collected solution was recirculated for 3.5 
hours. At the conclusion of the experiment, the cannula was removed 
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Figure 5. Schematic diagram of the rabbit non-surgical perfusion 
technique (old). 
Source: Mehta et al., 1990. 
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from the nasal cavity by pushing the cannula into the esophagus, 
rotating it 900, and slowly removing from the mouth. The rabbit was 
then placed on its side to remove any perfusate remaining in the 
nasal cavity. Finally, the endotracheal cannula was removed and the 
animal was returned to the cage after monitoring for short period. 
3.2.2 New non-Surgical Perfusion Technique (New Method): 
The rabbit was anesthetized as described above. After placing 
the animal on its back, a hard polyethylene tube was inserted by 
mouth into the trachea in order to allow the rabbit to breathe while 
the nasal cavity was being perfused by drug solution. A soft 
polyethylene tube was inserted into right nostril of the rabbit. To 
prevent leakage of the solution through the same nostril, a 
combination of a silicone ear plug and a copolymerized polymer was 
used to plug the nostril. The rabbit head was placed at an angle of 
150 downwards from the horizontal plane. Figure 6 shows the 
experimental set up for the new technique. The other end of the 
cannula coming out of the nostril was connected to a perfusion pump 
and the placement of the cannula was tested by infusing a small 
amount of saline solution through the nasal cannula and observing 
saline flow from the left nostril. 20 ml of insulin solution was 
perfused at a rate of 10 ml/hr and the collected solution was 
recirculated for 3.5 hours. At the conclusion of the experiment, the 
cannula and sealed plug were removed from the nostril and the 
rabbit was then placed on its side to allow drainage of any perfusate 
remaining in the nasal cavity. Finally , the endotracheal cannula was 
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Figure 6. The experimental setup for new non-surgical perfusion 
technique in rabbits. 
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removed and the animal was returned to the cage after monitoring 
for a short period. 
3.2.3. Study Design: 
Five New Zealand white male rabbits weighing 3.0 to 5.5 kg 
were fasted for 14-16 hours prior to the experiment. The study 
design used in this project was a randomized crossover with a wash 
out period of at least one week between treatments. 
3.2.4 Preparation of Solutions: 
(a) Perfusion Solution: Perfusion solutions were prepared by 
dispersing IOU/kg of bovine insulin in 0.057M isotonic phosphate 
buffer (pH 7.4 ). 0.05% w/v of sodium taurocholate was dissolved in 
the perfusion solution as a permeation enhancer. A constant volume 
of 20 ml solution was used throughout each perfusion study. 
(b) Spray Solutions: Solutions for administration by nasal spray 
were prepared by dispersing various doses of bovine insulin 
(IOU/kg, 5U/kg, 2.5U/kg and 1.25U/kg) in 0.057M isotonic 
phosphate buffer (pH 7.4 ). All the solutions contained 1 % w/v of 
sodium taurocholate as an enhancing agent. Sprays were 
administered in the nasal cavity using a spray pump that delivers 50 
µ 1 after each actuation. A volume of 100 µI was delivered during 
each treatment. 
(c) Subcutaneous Injection Solution: Bovine insulin (0.25 U/kg) 
was dispersed in 0.057M isotonic phosphate buffer (pH 7.4 ). 
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3.2.5. Preparation of Mucoadhesive Microspheres: 
Carbopol 934, a linear chained carboxylated poly(acrylic acid) 
polymer was cross-linked with the disaccharide maltose, using a W/0 
emulsification technique to form mucoadhesi ve microspheres. The 
microencapsulation procedure used was same as that described by 
Lewis et al. (1990). An aqueous phase consisting of 1.0 gm of 
polyacrylic acid and 0.1 gm of maltose dissolved in 30 ml of purified 
water was prepared. An organic medium consisting of 100 ml of 
olive oil containing 0.4 gm of palmitic acid was used. Since palmitic 
acid is an endogenous lipid, any residual amounts present in the 
microspheres should be pharmaceutically acceptable. Both the 
organic and aqueous mediums were placed in a wide mouthed bottle 
ands stirred at 1600 rpm. Within several minutes a fine emulsion 
was produced. An electrothermal isomantle was then placed under 
the flask and the emulsion was heated to 90 - 98 oc for 4.0 hours 
until the oil appeared clear and the microspheres were cured. The 
cooled mixture was poured into a large beaker containing 200 ml 
acetone. The flask was washed thoroughly with a further 100 ml of 
acetone. The supernatant was removed from the sedimented 
particles. The microspheres were washed repeatedly with acetone 
until no trace of oil could be detected. The microspheres were dried 
and stored under vacuum. 
Due to the high temperature involved in the cross-linking 
process, insulin had to be incorporated into the synthesized 
microsphere by swelling the particle rn a solution of drug followed 
by dehydration under vacuum. This was accomplished by placing 
500 mg of microspheres into a 20 ml glass vial containing 2.5 ml of 
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( insulin solution (1.0% w/v). The microspheres were hydrated with 
insulin solution overnight and subsequently vacuum dried to obtain 
a free flowing powder. In this way, insulin loaded microparticles 
were produced which could be solvent activated. That is, the drug 
was locked into place by the surrounding molecular chains of the 
polymer, and when exposed to an environmental fluid the polymer 
would swell, allowing insulin to diffuse outward. Excess drug in the 
original solution will be associated with the polymer on the surface. 
The polyacrylic acid aqueous gel base for insulin microparticles 
was prepared by presoaking polyacrylic acid (1 % w/v) in distilled 
water for 15 hours at room temperature and adjusting the pH to 6.0 
by adding concentrated solution of sodium hydroxide (Morimoto et 
al., 1985). 
3.2.6 Administration of Insulin to Rabbits: 
For perfusion studies, a constant volume of 20 ml of insulin 
solution (lOU/kg) containing 0.05% w/v sodium taurocholate was 
used. The perfusion was carried out for 3.5 hours at a rate of 10 
ml/hr. 
Spray formulations were delivered into the nasal cavity of 
rabbits by spray pump. 50 J11 was delivered in each nostril and an 
overall volume of 100 J1 l per rabbit was given. 
For subcutaneous injection, each rabbit received 0.25 U/ kg 
through the hind leg. 
The insulin microparticles freeze dried together with 
polyacrylic acid (IOU/kg) were suspended in l gm of polyacrylic acid 
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aqueous gel base (1 % W /Y). This formulation was administered to 
the nasal cavity by means of a synnge. 
3.2.7 Analytical Method: 
The absorption of insulin was measured by monitoring the 
blood glucose levels in the rabbits. The instrument used was an 
Accu-chek II blood glucose monitor which is a battery operated 
reflectance photometer that measures glucose photoelectronically rn 
whole blood when used in conjunction with Chemstrip bG test strips. 
The determination of glucose in whole blood with Chemstrip bG test 
strips is based on the glucose oxidase/peroxidase reaction. Each 
reagent strip has two test pads which contain color indicators, and 
the enzymes glucose oxidase and glucose peroxidase. When whole 
blood is placed on the test pads, D-glucose is oxidized to gamma- D-
gluconolactone with glucose oxidase acting as a catalyst. The 
hydrogen peroxide resulting from this reaction oxidizes the 
indicators in the presence of peroxidase. The intensity of the colors 
formed is proportional to the glucose concentration in the specimen. 
When the reacted strip is placed in the instrument, the color 
intensity of each test pad is evaluated by the double track optical 
system and converted to a numerical blood glucose value which is 
displayed on the LCD screen. 
The instrument was tested initially using standard control 
solutions with a concentration of 66 and 312 mg/dl as provided by 
the manufacturer (Table 3). 
(a) Accuracy: The accuracy of the analytical method was 
determined using a standard control solution with a glucose 
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concentration of 66 mg/dl. The experiment was run six times per day 
and on each of three different days. The observed mean and 
standard deviation were calculated using n= 18 (Table 3 ). 
If one considers the random error to be the width of the 
Gaussian distribution at a specified confidence interval of 99% 
(estimated by ± 2.58 x S.D), the accuracy of the method can be 
obtained as the difference between the measured mean (x), and the 
true value (µ) (Karnes et al., 1991). For this set of samples: 
Observed value (x) = 68.3 mg/di, S.D = 2.7, n=l 8 
True value (µ) = 66.0 mg/di 
Accuracy = absolute value of (x-µ) 
= 68.3 - 66.0 = 2.3 mg/dl 
Total error (E) can be calculated as: 
E = absolute value of (x-u) ± 2.58 x S.D 
= (68.3-66.0) ± 2.58 x 2.7 = (-4.7 mg/dl, 9.3 mg/dl ) 
(b) Precision: According to the manufacturer, Accu-chek II can be 
used to reliably measure blood glucose levels accurately in the range 
of 20 to 500 mg/dl. To determine the accuracy of the instrument 
within this range, glucose levels in blood were varied and the 
observed values were compared with the predicted values. Six 
samples were measured to obtain the mean and standard deviation 
in each case. Initially, rabbit blood was collected and assayed for 
glucose levels using Accu-chek II (Table 2). Then the glucose 
concentration was increased by adding 5% dextrose solution to a 
series of different levels: 152.7, 168.5, 212.0, 252.7 mg/dl. The 
observed mean values (± S.D) from these samples were 152.3± 3 .4, 
171. 7 ± 2.0, 208.2± 1.3 and 248.3±4.6 mg/dl respectively. To check the 
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Table 2. Blood Glucose Assay Using Accu Chek 11 to Determine Accuracy and Precision 
BLOOD GLUCOSE LEUEL (mg/di) 
no Bldl Bld:solA2 Bld:solA2 Bld:sol83 Bldl Bld:P04 Bid 1 Bld:P044 
1 : 1 1 :2 1 : 1 2:3 2 dilution s 
1 106 148 170 254 78 28 120 209 
2 109 155 173 239 81 25 11 9 206 
3 109 149 172 251 82 31 11 4 209 
4 106 156 174 250 85 38 11 4 207 
°' 
5 99 156 168 248 82 34 1 1 7 209 
...... 
6 104 150 173 248 82 29 1 1 6 209 
Me en 1 05.5 152.3 171. 7 248.3 81.7 30.8 1 1 6. 7 208.2 
(SD) (3.4) (3.4) (2.0) ( 4.6) (2.2) ( 4.6) (2.5) ( 1. 3) 
EHpected 
values - 152.7 1 68.5 252.7 - 32.7 - 21 2.0 
------------------------------------------------- - -
1. Blood wes collected from rabbits 
2. 1 ml of 5<Jo deHtrose solution wes diluted to 25 ml with isotonic phosphate buffer 
3. 2 ml of 5% deHtrose solution wes diluted to 25 ml with isotonic phosphate buffer 
"'·Glucose leuel was increased to 1038.7 mg/di end then diluted with phosphate buffer. 
sensitivity of the method, blood was diluted with phosphate buffer to 
obtain a minimum glucose level of 32.7 mg/dl and the observed 
value was 30.8± 4.6 mg/dl. Blood glucose level was increased to 
1038.7 mg/dl by adding 5% dextrose solution. Since the glucose 
levels higher than 500 mg/dl could not be measured, the test 
solution containing 1038.7 mg/di was diluted with phosphate buffer 
to bring the glucose level within the measurable range (346 mg/dl). 
The observed mean value was found to be 375.2± 6.3 mg/dl. The 
observed values were plotted against the expected values in Figure 7 
and a correlation of 0.997 was seen. 
(c) Reproducibility: The standard control solution with a glucose 
concentration of 66.0 mg/dl was measured on each three days to 
determine the reproducibility of the assay. The results as seen in 
Table 3 show that the mean observed values (± S.D) on these three 
days were 67.0±2.1, 69.3±2.6 and 67.8± 1.7 mg/dl. At a 99% 
confidence level, the observed glucose levels were not significantly 
different from each other. 
(d) Sampling: Fresh blood was collected from the ear vern of the 
rabbit and tested for glucose levels at different times. In all the 
studies, blood samples taken from the ear vein at -40, -20, -10, 15, 
30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 210, 240, 300, 360 
and 420 minutes after administration of insulin formulations. 
3.2.8 Data Analysis: 
Quantifying absorption requues either companng plasma 
insulin levels after injecting insulin, where absorption is assumed to 
be complete, or comparing the response caused by the absorbed 
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Table 3. Reproducibility of The Blood Glucose Assay Using Ac cu Chek 11 
BLOOD GLUCOSE LEUEL (mg/di) 
no CONTROL(high) CONTROL(low) 
dayt day2 day3 
1 309 64 70 66 
2 315 67 74 67 
3 320 69 68 66 
4 305 69 69 69 
°' 
5 309 68 69 69 
VJ 6 303 65 66 70 
Mean 31 0.2 67.0 69.3 67.8 
(SD) (5.8) ( 2. 1 ) (2.6) ( 1. 7) 
EHpected 
Uatues 31 2.0 66.0 66.0 66.0 
I insulin by quantifying the change in plas ma glucose concentration. 
The extent of absorption or efficacy rel ative to injected insulin is a 
primary determinant of the feasibility of the noninjectable insulin 
dosage forms. In this study, the insulin efficacy was compared after 
nasal administration under uniform experimental conditions. Efficacy 
was estimated relative to the subcutaneous route. Blood glucose 
levels were determined as a measure of insulin efficacy. Apparent 
pharmacokinetic parameters were calculated following nasal and 
subcutaneous administration of insulin. The area under the curve 
(AUC) was calculated based on the mean difference in the glucose 
level from the controls using the trapezoidal rule. The apparent 
bioavailability was calculated based on a comparison of the effect 
observed when a subcutaneous injection of 0.25 U/ kg was given. 
App. bioavailability = (AUCnasal x Doses.c)/(A UCs.c x Dosenasal) x 100 
The SAS software package was used to analyze data obtained 
during this srudy. Split-plot design and Least Significant Difference 
(LSD) were used to analyze whether the drug treatments were 
significant or not at 95% confidence interval (Hicks, 1982). 
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4. RESU LTS AND DISCUSS IO N 
The rabbit was used as an animal model in this study as it 
offers certain advantages when compared to other animal models. It 
provides large nostrils and large nasal surface area that is 
comparable to that of human beings. The rabbit is relatively 
inexpensive, readily available, and easily maintained in the 
laboratory setting. 
Insulin was used as the model drug as it provides the 
challenges of a typical polypeptide in delivering through the nasal 
membrane. An improved means of insulin delivery would also 
alleviate the difficulties faced by the diabetic patients. 
The original objective was to set up and validate an animal 
model and then to proceed to evaluation of formulation development 
of inatranasal drug delivery. 
4.1 Perfusion by Old Non-Surgical Technique: 
The animal model developed by Mehta et al. (1990) usrng a 
non-surgical perfusion technique was selected for our use srnce the 
non-surgical nature of the technique would allow the animal to act as 
its own control and hence the interanimal variability could be 
minimized. 
Initially , perfusion studies were carried out with the rabbit as 
the animal model and the performance and reproducibility of thi s 
system were determined. The experiments were carried out 
perfusing 20 ml of insulin solution (IOU/kg) containing 0.05 % w/v 
sodium taurocholate as a permeation enhancer. The control 
experiment involved perfusion of an 0.057M isotonic phosphate 
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( buffer. The results obtain ed dur in g this study are given in Table -I-. It 
can be seen that perfusion studies using the isotonic phosphate 
buffer, resulted in an immediate increase in glucose levels with a 
maximum of 297 .0± 32.5 mg/dl after 45 minutes of perfusion and 
then the glucose levels were gradually reduced over a seven hour 
period. In case of perfusion of insulin solution, the highest blood 
glucose levels were observed at 15 minutes and then the glucose 
levels were lowered gradually when compared to controls, 
presumably due to the absorption of insulin into the systemic 
circulation. Figure 8 shows that the lowest glucose levels (69.7 ± 8 .4 
mg/dl) were observed approximately after 165 minutes of perfusion. 
During this study certain difficulties were encountered. The 
technique was complex and didn't provide reproducible results. The 
rabbits could not be reused as the nasal cavity was often damaged 
during the placement of the cannula. Thus this technique resulted m 
not only variable results but also a loss of rabbits. Since the same 
rabbits could not be used for crossover studies, the rabbits could not 
act as their own controls. All these factors led us to develop an 
improved non-surgical perfusion technique. 
4.2 Perfusion by New Non-Surgical Technique: 
A new non-surgical technique was developed that can be 
considered relatively simple when compared to the . original 
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Tobie 4. 
Time 
(min) 
-40 
- 30 
-20 
- 10 
0 
1 5 
30 
45 
60 
75 
90 
105 
120 
135 
Glucose Concentration os o Function of Time During Perfusion of Insulin ond 
Buffer Solutions Using The Old Non-Surgical Perfusion Technique 
Blood glucose leuel (mg/di) 
Phosphate buffer Insulin solution 
Mean+s.Ea Mean+S.Eb 
128.8±4.6 117.2±10.2 
administration of anesthetics 
151.3±13.4 
170.3±8.5 197.0±25.8 
nasal administration of insulin 
265. 7±6.2 336.0±43.0 
269.0± 19.3 324. 7±45.8 
297 .0±32.5 
266.7±11.3 
268.3± 1 8.1 
262. 7±9.0 
262.0±6.7 
241.3±14.1 
245.3± 1 5.4 
272.5±26.3 
21 4.0±9.0 
182.7±16.0 
146.2± 18.1 
105.2±12.6 
99.0±8.4 
83.5±3.3 
a 
r 
°' 00 
Tobie 4. 
Time 
(min) 
150 
165 
180 
210 
240 
300 
360 
420 
(Continued) 
Bl~od glucose leuel (mg/di) 
Phosphate buffer Insulin solution 
Meon+s.Ea Mean+S.Eb 
245. 7± 19.4 74.0±6.2 
245~±26.9 69.7±8.4 
227.3±22.3 70.5±9.5 
21 3.0±27 .2 85.3±9.7 
227. 7±55.2 74.2±14.8 
219.7±47.2 88.3±7.5 
232.0±60.9 93.3±6.8 
213.7±52.0 98.3±9.6 
a .05 M isotonic phosphate buffer, pH=7.4, n = 3 
b 1 OU/kg insulin + 0.05% NaTC solution, n = 4 
S.E-Standard Error 
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Figure 8. Blood Glucose as a Function of Time During Perfusion of 
Insulin and Buffer Solutions Using The Old Non-Surgical Technique 
methodology. Table 5 summanzes the results obtained by perfusing 
insulin solution (1 OU/kg) containing 0.05 % sodium taurocholate. As 
shown in the Figure 9, when isotonic phosphate buffer (pH 7.4) was 
perfused without insulin, there was a rise in blood glucose levels 
from 117.2±4.9 to 265.8±23.6 mg/dl after administration of the 
anesthetics. Maximum blood glucose levels (265.8± 23.6 mg/dl) were 
observed after 60 minutes. The blood glucose levels returned to 
normal after 6.0 hours. When insulin solution was perfused, a similar 
increase in glucose levels was observed. In this case, the perfusion of 
insulin solution resulted in a gradual reduction of glucose levels. The 
lowest average concentration of glucose was 88.8± 5.4 mg/dl at 240-
300 minutes after beginning of the perfusion. 
The new technique, when compared to the old non-surgical 
perfusion technique, offers many advantages. The new technique 1s 
very simple and the animals can be reused without causing any 
damage to the nasal cavity. Placement of the cannula is much easier 
and requires less skill and/or practice than the old technique. 
Moreover the results are very reproducible. The results showed that 
the absorption was less in case of new technique when compared to 
the ol_d technique. Figure 10 shows that the glucose reduction in case 
of old technique was higher and occurred rn less time as compared to 
the new technique. The higher absorption of insulin with the old 
technique could be due to absorption of the drug in the throat. The 
drug solution might be entering the throat due to improper 
placement of the cannula. This was confirmed as the experiments 
progressed by the very variable and reduced quantities of perfusate 
collected from that originally added with the old technique. 
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Table 5. 
Tl ME 
(min) 
-40 
- 30 
-20 
-10 
0 
1 5 
30 
45 
60 
75 
90 
105 
120 
135 
Glucose Concentration as a function of Time during Perfusion of Insulin and 
Buffer solutions Using The New Non-Surgical Perfusion Tecvrnique 
BLOOD GLUCOSE LEUEL (mg/di) 
Phosphate buffer Insulin solution 
Mean+s.Ea Mean+s.Eb 
117.2±4.9 113.3±5.8 
administration of anesthetics 
151.0±12.3 143.3±2.8 
189.0±12.3 188.8±13.9 
nasal administration of insulin 
238.6±23. 7 239.5± 12.8 
260.8±27.6 253.7±16.2 
252.4±21.3 249.2± 18.0 
265.8±23.6 230.7±20.3 
258.4±23.7 213.3±18.4 
259.8±22.0 193.3±25.2 
255.6±20.9 180.5±25.4 
240.6± 1 5.6 153.7±24.3 
225.6±14.7 143.3± 18.4 
.......) 
N 
Tllble 5. 
Time 
(min) 
150 
165 
180 
210 
240 
300 
360 
420 
(Continued) 
Blood glucose leuel (mg/di) 
Ph osphll t e bu ff er Insulin so'lu tio n 
Me11n+S.[ll Me11n+S.Eb 
220.6± 11.8 126.0±19.2 
211.8±15.7 119.2±16.8 
199.2±14.1 108.8±11.3 
176.2±14.0 100.5±12.8 
158.4± 14.5 92.0±10.2 
132.0±4.8 88.8±5.4 
117.8±1.8 107.8±9.2 
107.8±3.7 11 6.2±9.0 
a 0.05 M isotonic phosphate buffer, pH=7.4, n = 5 
b 1 OU/kg insulin + O.OS°lo NaTC solution, n = 6, S.E-Standard Error 
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Figure 9. Blood Glucose as a Function of Time During Perfusion of 
Insulin and Buffer Solutions Using The New Non-Surgical Technique 
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Figure 10. Comparison of the Reduction in Blood Glucose 
Using the Two Non-Surgical Perfusion Techniques 
.---.. 
( Compared to the surgical technique (Hirai et al., 1981 a), the 
new non-surgical perfusion technique offers many advantages. The 
obvious advantage is the simplicity of technique which does not 
require surgery. A second advantage is the reusability of animals 
after each experiment. In previous cases where surgery is involved, 
the animals had to be sacrificed resulting in not only increased cost 
but also the animals can not act as their own controls. Hence a 
crossover study is not feasible with the Hirai animal model. The 
present technique will enable the researchers to utilize the crossover 
studies to reduce inter-animal variability which often produces 
discrepencies in extrapolating data in animals to humans (Adjei, 
1990; Baldwin et al., 1990; Deurloo, 1989). Although the rabbit was 
used as animal model in this study, it is expected that the new non-
surgical perfusion technique can be applied to other animals without 
modification. 
4.2.1 Physicochemical Parameters to be Considered During 
Perfusion Studies: 
(a) Effect of Anesthetics: 
During these studies, a significant increase m glucose levels was 
observed after administration of the anesthetics. To better define 
this observation, a control experiment was carried using two 
different anesthetic combinations. Table 6 shows the effect of 
anesthetics on blood glucose levels in rabbits. Sodium pentobarbital 
did not exhibit any increase m blood glucose levels as evident from 
Figure 11 . The combination of anesthetics used in the perfusion 
studies i.e. ketamine hydrochloride , acepromazme maleate and 
75 
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Table 6. 
TIME 
(min) 
-40 
-30 
-20 
-10 
15 
30 
45 
60 
75 
90 
105 
120 
135 
Effect of Anesthetics on Blood Glucose Leuels in Rabbits 
BLOOD GLUCOSE LEUELS (mg/di) 
Controlsa Contro1sb 
Mean+S.E Mean+S.E 
112.3±3.7 98.3±5.2 
administration of anesthetics 
132.8± 1 0.9 102.7±9.6 
171.1±17.3 90.7±8.2 
221.1±22.6 89.7±5.7 
226.6±23.4 89.0±4.0 
225.1 ±23.6 90.3±4.4 
229.6±22. 7 88.0±2.6 
227.5±22.4 89.7±3.3 
230.5±21.7 88.7±4.2 
219.5±21.6 
216.4±1 9.4 84.7±4.7 
205.6±17.5 
-.J 
-.J 
Table 6. (Continued) 
---'----------·--
TIME BLOOD GLUCOSE LEUELS (mg/di) 
(min) Controlsa Controlsb 
Mean+S.E Mean+S.E 
150 186.9±15.4 95.7±12.7 
165 178.6±16.3 
180 170.3±16.0 90.7±8.3 
210 153.1±13.3 92.0±7.2 
240 142.9±11.1 94.7±7.2 
300 128.5± 1 2.2 89.3±3.2 
360 114.5±8.0 90.7±4.9 
420 117.6±11.5 90.0±4.6 
a Anesthetics used: Ketamine Hydrochloride, Acepromazine Maleate, and Hylazine 
Hydrochloride, n=B 
b Anesthetics used: Pentobarbital Sodium, n=3 
·---
' 
' 
~ 
f . 
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Figure 11. Effect of Anesthetics on Rabbit Blood Glucose Levels 
( xylazine hydrochloride caused a rapid n se in blood glucose levels 
within 10 minutes after administration. Maximum glucose levels 
(230.5±21.7 mg/dl) were observed at 90-120 minutes after 
administration. The glucose levels returned to normal after 
approximately 7 .0 hours. These results were found to be very 
consistent and reproducible throughout the study in all the rabbits . 
Sodium pentobarbital did not cause any change in blood glucose 
levels, but could not be used in this study as it provides anesthesia 
for only 45 minutes and subsequent doses may cause death to the 
rabbits. For these perfusion studies, anesthesia of 4 to 4.5 hours was 
required and the above mentioned combination of drugs provided 
constant deep and safe anesthesia. Since the change in blood glucose 
levels was consistent and predictable, the same combination of 
anesthetics was used throughout the study to maintain the uniform 
conditions. 
The mechanism for the increase m blood glucose levels by 
anesthetics is not very clear. Ketamine may be increasing plasma 
epinephrine and norepinephrine levels upon injection which may 
cause glycogenesis in liver cells (Katzung, 1989; Kahn et al., 1991). 
Glycogenesis is the conversion of glycogen to glucose, which might be 
the reason for the high glucose levels observed after injection of 
anesthetics. 
(b) Positioning of The Rabbit Head: The nasal cavity is like a 
bowl. When perfusion is initiated, this cavity is filled with perfusate 
water and the excess solution starts flowing from the left nostril. The 
placement angle of the rabbit head is very critical. If the angle is too 
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( high, the head will be inclined too low, the cavity will not be filled 
and lower absorption will result. If the angle is above the horizontal 
plane, solution will be lost down the throat resulting an ever 
decreasing volume of perfusate. In this study, the rabbit head was 
placed at an angle of 140 -150 from the horizontal plane. The amount 
of perfusate collected was a constant 18 to 19 ml out of 20 ml 
throughout the testing which confirmed proper placement of head to 
achieve maximum and reproducible absorption for each formulation. 
(c) Other Factors: Other factors which would influence the 
absorption of insulin from the nasal cavity are: the rate at which 
insulin solution was perfused, volume of the perfusate, the time of 
perfusion (Huang et al., 1985, 1985a) and the pH of the perfusate 
(Hirai et al., 1978). In this study all of these parameters were held 
constant to minimize the affect on the aborption of insulin. Further 
studies are required to define the specific effect of each parameter. 
4.3 Evaluation of Nasal Formulations: 
After establishing the experimental conditions for the new 
perfusion technique and validating the rabbit as the animal model, 
the se_cond phase of this project was to evaluate the comparative 
bioavailability of vanous nasal formulations of insulin using this 
model. The formulations to be compared with the perfusion 
technique were sprays containing different doses of insulin, 
polyacrylic acid microparticles loaded with insulin, as well as a 
subcutaneous injection of insulin to establish baseline parenteral 
bioavailability. 
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4.3.1 Spray formulations: 
Spraying a formulation into the nasal cavity is the most 
popular and convenient means of delivering nasal products . For most 
of the drugs designated for nasal administration , the final dosage 
form will be a spray formulation. The reasons are obvious: spraying 
of drugs results in rapid absorption and in high plasma levels 
similar to those observed after an i. v. injection. Sprays result in the 
deposition of material on the nonciliated regions and hence the 
clearance of sprays is slower compared to drops. This results in 
increased absorption rates when as compared to nasal drops. Sprays 
are easy to administer and very convenient thus giving increased 
patient compliance. Sprays provide consistent dosing as compared to 
powders and drops. 
Spray formulations containing a senes of increasing doses of 
insulin were evaluated (1.25, 2.5, 5.0, 10.0 U/kg) using the rabbit 
model. All the sprays contained 1 % w/v of sodium taurocholate as an 
enhancer. The results are summarized in Table 7 and shown in 
Figure 12. Spray 3 (lOU/kg) resulted in lowest glucose levels of 
3 8. 3 ± 1.15 mg/dl at 60 minutes. It was possible to replicate this 
lOU/kg dose in only three rabbits because lOU/kg was found to be 
fatal dose for some rabbits due to the rapid absorption of this large 
amount of insulin. Spray 4 (5U/kg) gave minimum glucose levels 
( 4 7.4± 9.9 mg/dl) at 60 minutes. In case the of Spray 5 (2 .5U/kg), the 
lowest glucose levels 87.4± 11 .1 mg/di were observed at 45 minutes. 
The spray 6 formulation containing 1.25 U/kg of insulin resulted m 
minimum levels of 102.7± 14.4 mg/dl at 90 minutes after 
administration of the spray into the nasal cavity. When compared to 
8 1 
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THble 7. Effect of Insulin SprHy FormulHtions on RHbbit Blood Glucose Leuels 
--------------
Time MEAN BLOOD GLUCOSE LEUELS (mg/di) 
(min) SprHy3H SprHy4b SprHy5C Sprey6d 
-40 107.7±6.4 106.0±2.9 103.0±6.7 99.6±4.1 
- 30 administration of anesthetics 
-20 125.7±0.3 125.6±4.6 120.2±4.2 117.4±3.7 
-10 145± 13.4 143.4±4.2 152.0±11.3 165.2±13.0 
0 nasal administration of insulin spray 
00 1 5 92.1 ±9.5 105.4±6.7 144.4± 12.9 152.2±15.9 N 
30 70.7±12.8 70.6±8.6 98.7±9.8 127.3±14.9 
45 58.0± 14.6 53.4±8.4 87.4±11.1 110.0±16.1 
60 38.3± 1.1 5 47.4±9.9 89.3±14.8 112.4±18.4 
75 59.9±17.7 52.9±9.6 88.5±13.3 105.9+18.3 
90 77 .2±31 .5 58.4±7.8 94.3± 13.4 102.7±14.4 
105 72.9±17.1 
120 74.2±16.5 65.4±7.9 98.4± 15.3 107.0±14.3 
135 60.1 ±2.2 
00 
VJ 
Tobie 7. (Continued) 
Time 
(min) 
150 
165 
180 
210 
240 
300 
360 
420 
8 
b 
c 
d 
MEAN BLOOD GLUCOSE LEUELS (mg/di) 
Sproy3o Spniy4b Spray5c Sprny6d 
75.0±16.1 71 .6±5.4 103.2±15.6 105.8±11 .5 
60.4±4.5 
75.7±14.4 74.1 ±6.2 99.1±12.1 109.0±13.1 
75.4± 15.2 71 .6±6.3 101.5±12.0 105.4±10.2 
64.7±10.8 4.7±8.3 98.5±11.9 105.3±10.0 
77.3±13.5 81 .3±8.4 1 06.5±5.5 98.6±6.8 
85.7±14.9 82.3±5.4 99.9±5.6 101.2±11.1 
85.3± 12.2 84.5±5.1 111.5±7.9 108.8±17.6 
Dose - 1 O U/kg insulin + 1 '7o w/u sodium taurocholate, n = 3 
Dose - 5 U/kg insulin + 1 '7o w/u sodium taurocholate, n = 5 
Dose - 2.5 U/kg insulin + 1 '7o w/u sodium taurocholate, n = 5 
Oose - 1.25 U/kg insulin + 1 '7o w/u sodium taurocholate, n = 5 
00 
~ 
300 l I~- Comrols, n=8 
+-- Spray 3 (IOU/kglnsulin+l % NaTC), n=3 
,........ I Tlllll 1--0-- Spray 4 (5U/kglnsulin+ I% NaTC), n=5 
-
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Figure 12. Blood Glucose Concentration as a Function 
of Time After Administration of Insulin Nasal Spray 
the controls, as the insulin dose was lowered from lOU/kg to 1.25 
U/kg, the insulin effect in terms of g lucose reduction was reduced 
gradually. 
4.3.2 Comparison of spray and perfusion: 
Figure 13 compares the results obtained using the new 
perfusion technique and a comparable nasal spray. Spray 3 
containing IOU/kg of insulin resulted in an immediate reduction m 
glucose levels. Minimum levels were observed at 60 minutes . The 
perfusion method resulted in a gradual reduction in glucose levels. 
The lowest levels were observed after 240-300 minutes. The 
absorption of insulin from the nasal spray was faster compared to 
the perfused insulin solution. The reasons for this may be the higher 
concentration of enhancer present in the spray (lmg/100µ 1) 
compared to the perfusion solution (1 Omg/20ml). It has been 
reported that as the concentration of enhancer increases, drug 
absorption will increase (Lee, 1990). Another reason may be that, for 
the spray all the insulin (IOU/kg) was in 100 µ 1 and administered at 
one time. Whereas in the case of perfusion, the same amount of 
insulin (IOU/kg) was supplied to the nasal cavity in 20 ml of solution 
and over a 3.5 hour period. 
The exact mechanism of action of sodium taurocholate is not 
known . However, it is thought to involve both solubilization of 
insulin, and the direct effect of the surfactant on cell membranes 
perhaps involving reverse micelle formation (Gordon et al., 1985). 
The addition of bile salt is thought to result in formation of mixed 
micelles of bile salt and insulin as insulin monomers (Gordon et al., 
1985). When sprayed into the nasal passages, a high transmembrane 
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Figure 13. Comparison of Blood Glucose Levels After Administration 
of Insulin by Nasal Spray and Perfusion methods 
concentration gradient of solubilized in sulin monomers would serve 
to drive insulin transport across the mucosal barrier. Sodium 
taurocholate may also increase the membrane permeability by 
loosening the intercellular junctions and/or by increasing the 
number of pores in the cell membrane (Birkett et al., 197 4 ). It is well 
known that a polypeptide such as insulin is subjected to degradation 
by proteolytic enzymes during passage through the mucosal 
membrane. However, it has also been reported that the addition of 
bile salts resulted in inhibition of the enzymatic degradation of 
insulin and of the enzymatic activity of leucine aminopeptidase, 
which rapidly breaks down the B-chain of insulin from the 
hydrophobic N-terminal end (Hirai et al., 198lb). Never the less 
additional studies are required to determine the relationship 
between the enhancer concentration used rn perfusion formulations 
and that utilized in spray formulations as well as the different 
mechanism of providing increased absorption shown by the different 
enhancers. 
The bioavailability realized when testing formulations 
administered by different routes should be compared to a baseline 
level to evaluate the relative success of these efforts. Usually the 
amount of drug absorbed nasally is quantified by comparing the 
plasma levels of the drug or the biologic response after nasal 
administration to those levels observed after i. v. injection. Since 
insulin is usually given subcutaneously, the baseline response rn this 
project was obtained by injecting insulin subcutaneously and the 
nasal formulations were evaluated relative to this baseline response. 
Table 8 summarizes the results obtained following subcutaneous 
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Table 8. 
TIME 
(min) 
- 40 
- 30 
-20 
-10 
0 
15 
30 
60 
75 
90 
120 
150 
180 
210 
240 
300 
360 
420 
Obserued Blood Glucose Leuels After Administration of Insulin by Subcutaneous 
Route 
BLOOD GLUCOSE LEUELS (mg/di) 
Subcutaneousa 
1 04.0±5.1 
administration of anesthetics 
11 7 .0±2.2 
142.8±3.7 
administration of insulin 
205.6±8.2 
199.6±7.5 
149.4± 1 2.3 
125.4± 13.2 
1 06.8±9.3 
77.4±6.5 
68.0± 1.2 
62.0±2.9 
71.6±2.6 
71.2±2.1 
74.0±2. 7 
87 .8±6.1 
101 .2±6.2 
I} Dose - 0.25 U/kg of insulin, n = 5 
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Figure 14. Comparison of Blood Glucose Reduction After 
Administration of Insulin by Nasal and S.C. Routes 
injection. The subcutaneous injection of 0.25U/kg of insulin, as 
expected, resulted in slower absorption of drug from the injection 
site. As evident from Figure 14, the reduction in glucose levels after 
s.c. injection, started after 15 minutes with the lowest levels of 
62± 2.9 mg/dl observed approximately 180 minutes after injection. 
The pattern of glucose reduction was quite different from 1 OU/kg 
spray. The nasal spray resulted in immediate drop in glucose levels 
with minimum levels of 38.3± 1.15 mg/dl at 60 minutes after 
administration. Approximately 180 minutes after administration of 
s.c injection, the glucose levels returned to normal in a profile similar 
to that seen in the case of the spray formulations. 
4.3.3 Gel Formulation Containing Insulin Microparticles: 
Although, the inclusion of bile salts in formulations could 
provide a reasonable increase in the efficacy of transport and 
reproducibility of dosing (Pontiroli et al., 1982; Moses et al., 1983 ), 
there are serious concerns regarding the local toxic effects and 
irritation of the biological membranes by these compounds. There 
are reports in the literature indicating that cholic acid derivatives 
cause a breakdown of the mucous membrane structure (Martin et al., 
1976); accelerate phospholipid and protein release from membranes; 
and damage intestinal mucosa, Iiposomal membranes and isolated 
hepatocytes (Duchateau et al., 1986). Another problem faced in nasal 
drug delivery is that all solution formulations are cleared rapidly 
from the nasal cavity by the mucociliary clearance mechanism. The 
mucous blanket is replaced every 10-15 minutes thereby giving 
minimal contact time for absorption of the drug molecules. It is 
hypothesized that by increasing the contact time or residence time, 
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( increased absorption of drugs should res ult from the nasal 
membrane. Previous researchers have used bioadhesive polymers 
such as polyacrylic acid (PAA) and methyl cellulose to enhance the 
absorption of drugs from nasal cavity. Polyacrylic acid has also been 
used as an al tern a ti ve enhancer to promote the absorption of insulin 
(Nagai et al., 1984; Morimoto et al., 1985) and was preferred to bile 
salts as it is less irritating and less toxic to the nasal membrane . In 
this study, polyacrylic acid was cross-linked with maltose to obtain 
microspheres. The microspheres were loaded with insulin and 
freeze-dried to remove water from the system. The free flowing 
microparticles thus obtained were administered nasally in a 1 % w/v 
poyacrylic acid gel at pH-6.0. 
Polyacrylic acid microparticles loaded with insulin, when 
administered nasally in a gel base to the rabbits, resulted in lower 
glucose levels as compared to the controls. As evident from Figure 
15, initially there was an increase in the glucose levels due to the 
effect of anesthetics and then there was a gradual reduction in the 
glucose levels over a period of 5.0 hours. Maximum glucose levels of 
186.0±19.3 mg/dl were observed approximately 75 minutes after 
administration of gel formulation (Table 9). The observed glucose 
levels throughout 7 .0 hours were lower than those of the controls 
indicating that the formulation was providing controlled release of 
insulin. 
As evident in Figure 15, the spray provides a quicker response 
and a greater reduction in glucose levels. Polyacrylic acid is 
bioadhesive in nature and increases the residence time of 
9 1 
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Table 9. Obserued Blood Glucose Leuels After Administration of Insulin by Nasal Route 
TIME 
(min) 
- 40 
- 30 
- 20 
- 10 
0 
1 5 
30 
45 
60 
75 
90 
120 
150 
180 
210 
240 
300 
360 
420 
-
8 
BLOOD GLUCOSE LEUELS (mg/di) 
Nasal Gel formulationa 
114.6±3.9 
administration of an e~ th e ti c s 
131.6±3.2 
152.8±7.3 
administration of insulin 
177.4±18.8 
170.4± 1 6.4 
184.2+22.3 
181.4±21.1 
186.0±19.3 
1 82.4±22.2 
162.2±21.2 
148.6±22.9 
141.2±23.3 
131.6±16.5 
118.2±15.2 
94.2±8.3 
81.0±4.0 
88.2±7.4 
Polyacrylic microparticles were loaded with insulin ( 1 OU / kg) and administered with 1 '7o 
w/u polyacrylic acid gel at pH=6.0, n = 5 
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Figure 15. Comparison of Blood Glucose Reduction After 
Administration of Insulin by Spray and Gel Formulation 
formulation in the nasal cavity and thus provides a prolonged effect 
for a relatively less absorbed drug. 
4.4 Statistical analysis: 
A split-plot design was as used to evaluate the drug treatment 
effects on five rabbits over a time period of seven hours. Rabbit, type 
of treatment (formulation/administration) and time were the three 
factors used in the ANOV A procedure. 
The p value obtained from the ANOV A table for the rabbit, 
treatment and time factors is same, and is equal to 0.0001. There are 
significant interaction effects between treatment and time and 
treatment and rabbits (p=0.0001). No significant interaction effects 
were observed between time and rabbits. 
Least Significant Difference (LSD) test was used for paHw1se 
comparisons between means of treatments, time and rabbits. All the 
determinations of significance were made at the 95% confidence 
level. 
Controls were significantly different from perfusion (new), 
spray 4 (5 U/kg), spray 5 (2.5 U/kg), spray 6 (1.25 U/kg), s.c. and 
PAA micro particles (LSD=7. 9931 ). Perfusion of insulin (10 U/kg) 
solution using the new technique resulted in reduction in glucose 
that was significantly different from spray 4 (5 U/kg), spray 5 (2.5 
U/kg), spray 6 ( 1.25 U/kg), s.c. and PAA microparticles (LSD=7 .9931 ). 
Spray 4 (5 U/kg) resulted in significant glucose reduction in rabbits 
compared to spray 5 (2.5 U/kg), spray 6 (1.25 U/kg), s.c. and PAA 
microparticles (LSD=7 .9931). Spray 5 (2.5 U/kg) was found to be 
significantly different from spray 6 (2.5 U/kg), s.c. and PAA 
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microparticles. No significant differences were observed between 
spray 6 (1.25 U/kg) and s.c . injection. Glucose levels observed after 
administration of PAA microparticles ( 1 OU /kg) were found to be 
significantly different from those observed after administration of 
spray 6 ( 1.25 U/kg) and s.c. injection (0.25 U/kg). 
Significant differences were observed between three rabbits 
(LSD=6.7554). No significant differences were observed between the 
two remaining rabbits. 
4.5 Comparison of Apparent Pharmacokinetic Parameters: 
The mean differences in glucose levels for rabbits receiving the 
various formulations and those of the controls were used to assess 
the apparent pharmacokinetic parameters. The results are 
summarized in Tables 10&11 and shown visually in Figures 16&17. 
Cmax is the maximum difference in glucose level from that of control. 
The time at which maximum difference was observed is tmax . The 
observed values for Cmax and tmax are given in Table 12. 
The time at which the maximum effect observed was relatively 
same for all the spray formulations. The tmax values are 70± 10, 
63±7.3, 69±9 and 75±7.5 minutes for spray 3 (10 U/kg), spray 4 (5 
U/kg), spray 5 (2.5 U/kg), spray 6 (1.25 U/kg) respectively. No 
significant differences in tmax values were observed for spray 4 (5 
U/kg), spray 5 (2.5 U/kg) and spray 6 ( 1.25 U/kg). Subcutaneous 
injection of insulin and nasal gel formulation resulted in tmax values 
of 120± 18.4 and 222± 62.6 minutes respectively. The tmax value for 
s.c. injection differed significantly from those values for the spray 
formulations. The perfusion studies resulted in tmax values of 
147±20.3 minutes for the new technique and 180±60.9 minutes for 
95 
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Tobie 1 0. Comparison of Meon Deuiations in Blood Glucose Leu els Compared to Control s 
After Adminitration of Insulin Spray Formulations 
TIME 
(min) 
Mean Deuiations from Controlsa (mg/di) 
Spray 3b Spray 4c \ pr uy 5 d Sµni y 6e 
--------- - ---------------------· --------- --------· 
- 40 17.5±14.5 9.2 ±3.8 12.7.tS.3 l 11. 7 ±U. 2 
- 30 administration of ane s th e ti cs 
- 20 67.0 73.0 28 .3±2 1. 7 22 .0 ±13.S 
- 10 63.7±15.0 63.0 ±22.3 49 ±2 .1 4 1 .0 ±4 .0 
0 administration of insulin 
1 5 176.0±32.7 128.2±34.1 89.2 ±20.5 81. 4±29 .7 
30 200.5±21.6 171.2±24.2 143.1±19.8 114.5±29.8 
45 218.4±14.5 191.2±24.0 157.2±18.0 134.6±36.9 
60 219.1±23.3 199.2±17.8 157.3±12.1 134.2±39.7 
75 209.2± 13.8 188.3± 1 8.3 152.7±14.8 135.3 ±40.3 
90 214.1 ±20.8 187.4±23.3 151.5±21.1 143.1 ±39. 4 
120 171.1±20.1 164.0±19.9 131.0±22.7 122.4±36 .4 
-----
'° . 
-...) 
Table 10. (Continued) 
TIME 
(min) 
150 
180 
210 
240 
300 
360 
420 
-
a 
b 
c 
d 
e 
Mean Deviations from Controlsa (mg / di) 
Spray 3b Spray 4c SprBy 5d SprBy 6e 
128.3±22.5 129.3 ± 18.8 ') 5 .2 .!: 2 3 . H <Ji.6 :+: 3 1.3 
111.2±35.5 110 .7 ±22.7 107 .5± 13 .2 99.3 ±3 1. <J 
91.1±39.9 92.8 ±21.7 62.9 ±20 .8 7 8 .4±26 .6 
106.3±50.8 77.9 ±21.8 70 .4± 19 .'.j 47 .3±2 0. 3 
82.8±56.6 63.2 ±24.6 4 6.9 ±17 . 1 36.8±23 .9 
47.4±37.7 33.5 ±14.8 14.2± 7.7 28 .4± 16.4 
31.4±14.7 21.1 ±6.0 21.0 23.2 ±0.9 
Negative UBlues were not included while determining meBn UBlues 
Dose - 1 O U/kg insulin + 1 % w/u sodium tBurocholate, n = 3 
Dose - 5 U/kg insulin + 1 °lo w/u sodium taurocholBte, n = 5 
Dose - 2.5 U/kg insulin + 1 % w/u sodium tBurocholBte, n = 5 
Dose - 1.25 U/kg insulin+ 1 % w/u sodium tBurocholBte, n = 5 
'° 00 
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Figure 16. Comparison of Mean Deviations in Glucose Levels 
From Controls After Administration of Insulin Nasal Spray 
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Table 11. 
TIME 
(min) 
Comparison of Mean Oeuiations in Blood Glucose Leuels Comp tired to 
Controls After Adminitration of Insulin 
Mean deuiHtions from Control~ (mg / dl)H 
SubcutHneousb Gel c Perf11'1i o n(11 ~ 1 1 1)d l 't! r tu'li u 11 !11 i 
--------- -------------------- --··----·- ··--- -· --- . ----·- -
-40 16.3±4.2 15.5 ±6.5 10.7 ±4. 4 <\ u .5 
- 30 Hdministration of ane s theti cs 
- 20 20.5±18.5 56.0 38 ±17 .6 
-10 62.7±25.5 62.7±23.2 I 8. 5± 4. 5 ,19 . 7 ± 3 5 . n 
0 HdministrHtion of insulin formulHtion 
1 5 103.5±25.5 119.7±47.4 54±1.0 13.0 
30 76.0±40.1 128.0±48.1 47. 7 ±33.5 34.0 
45 92.5±32.9 127.3±36.8 39.0± 1 0.5 50.3±33.6 
60 97.2±31.9 124.0±39.1 75.7±26.2 48.0±12.8 
75 115.8±32.5 112.7±42. 7 100.7±6.2 79.8±11.8 
90 139.0±34.0 116.3±60.2 112.7±16.6 112.2±11.5 
120 1 52.0±29.5 116.7±62.7 81.8±31.9 137.7±5.8 
........ 
0 
0 
Tobie 11. 
TIME 
(min) 
150 
180 
210 
240 
300 
360 
420 
(Continued) 
Meon deuiations from Controlsa (mg/di) 
Subcutaneousb Gelc Perfu sio n(n e w)d Perfu sio n (ol :i r 
130.4±22.2 83.7 ±64.1 lJ l. U± l 8. I 1 63 .0 ~ .52 . "/ 
122.8±24.5 116.5±69. 5 85 .6 ±9. 3 147 .7± 15.8 
92.8±21.1 84.0 ±31.0 56.6 ±8 .9 12 7. 7±35.5 
81.4±17.5 47.7 ±18.2 62. 8± 7.7 13 8.7 ±43 .6 
51.8±19.1 36 .7±17.6 4 1.8± 7. 2 13 1. 3±53.5 
19.2±7.0 27.0±11.1 19.2 ±8.0 140.7±67.0 
6.5±2.6 26.5±2.5 18.0±13.0 1 1 5.3 ±61 .6 
a Negatiue ualues were not included while determining mean ualues 
b Dose - 0.25U/kg insulin, n = 5 
c Insulin microparticles (1 OU/kg) in 1 % w/u PAA gel at pH-6.0, n = 5 
" 
d Perfusate (20 ml) contoined 1 OU/kg .insulin and 0.05% w/u NtiTC in buffer (pH - 7. 4), n = 6 
e Perfusi:ite (20 ml) conti:iined 1 OU/kg insulin i:ind 0.05% w/u NtiTC in buffer (pH - 7.4), n = 3 
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Figure 17. Comparison of Mean Deviations in Glucose 
Levels From Controls After Administration of Insulin 
~ 
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Tobie 12. Comporison of Apporent Phormocokinetic Porometers After lntronasal 
Administrotion of Uorious Insulin Formulotions 
Formulotiono n TmoHb CmoHb AU[b, c %Apporent d 
.... 
Administration l! I I u El i I ti li 1 Ii t ij 
-------------------------------- ---- -------· - --- ----- .. --- -- --· 
S.C. injection 5 120.0± 1 8.4 1 6 5. <l .!: 2"/ . 7 J2 I 5'.J.~i :t 4lJlJ9.fi 
1 OU / kg Sproy 3 70.0± 10.0 224.4 !: 14 .5 4420 1.0±:7345.5 3 . -l · l 
SU / kg Spniy 5 63.0±7.3 2 0 7 . <I .t:: 2 3 . 2 4 I 7 5 0 . 'J :t 4 G ll 0 . ~1 6. 11 1 
2.5U/kg Sproy 5 69.0±9.0 168.8 ±18.5 30263.9 ±2 988.0 9.41 
1.25U/kg Sproy 5 75.0±9.5 154.7±39.8 29320.4±8223.5 18. 24 
1 OU/kg PAA gel 5 222.0±62.6 107.0±43.2 24118.1 ±7935.4 1.8 8 
Perfusion(new)e 6 147.0±20.3 116.2±18.2 20322.0±3445.3 1. 58 
Perfusion (old)e 4 180.0±60.9 193.3±29.1 49894.3± 13584.0 3.88 
a Sproy formulotions contained 1 io NBTC; Perfusions contBin 0.05% NBTC 
b Menn ± Stondord error 
c ColculBted from mean differences in glucose leuels from control using the trepezoid El l 
rule. 
d Apparent bioauailability = (AUCnosol H Ooses.c ) / (AUCs.c H Oosenas 6 1)H 1 00 
e 1 OU/kg insulin in 20 ml phosphate buffer perfused ouer 3.5 hrs. 
( the old method. No significant difference was observed between tm ax 
values observed between the two perfusion techniques . Howver the 
tmax value for new perfusion technique was significantly different 
from that obtained for spray formulations. 
The values for Cmax showed a gradual decrease as the dose was 
lowered from 10 U/kg to 1.25 U/kg. The observed values for Cmax 
for spray 3 (10 U/kg), spray 4 (5 U/kg), spray 5 (2.5 U/kg), spray 6 
(1.25 U/kg) were 224.4±14.5, 207.4±23.2, 168.8±18.5 and 154.7±39.8 
mg/dl respectively. No significant differences were observed in Cm ax 
values for the spray formulations. The observed Cmax values for the 
s.c. injection, gel formulation, the new and old perfusion techniques 
were found to bel65.4±27.7, 107.3±43.2, 116.2±18.2 and 193.3±29.1 
mg/dl respectively. The Cm ax value for spray 4 (5 U/kg) was found 
to be significantly different from that observed for new perfusion 
technique. No significant differences were observed in Cmax values 
for other formulations. 
The area under the curve (AUC) was calculated based on the 
blood glucose levels as a function of time using trepezoidal rule. The 
s.c. injection of 0.25 U/kg of insulin resulted in AUC of 
32155.5±4999.6 mg/dl minute. For the spray formulations, the AUC 
gradually increased from 29320.4± 8223.5 to 44201±7345.5 mg/dl 
minute as the dose was increased from 1.25 U/kg to 10 U/kg. A plot 
of AUC vs dose following nasal administration of the spray 
formulations is given in Figure 18. The graph shows the dose to AUC 
relationship after intranasal administration of insulin from spray 
formulations. However, there was no proportional increase in the 
AUC values when compared to the dose administered. The 
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explanations for the nonlinearity observed include a saturable 
binding and/or metabolism with membrane or enzyme systems . The 
new perfusion technique resulted in AUC values of 20322.0± 3 445. 3 
mg/dl minute. The AUC for Spray 4 (5 U/kg) was significantly 
different from that observed for Spray 6 (1.25 U/kg) and new 
perfusion technique. No statistically significant difference was 
observed between the AUC values for Spray 4 (5 U/kg) and s.c. 
injection (0.25U/kg) . The gel formulation (IOU/kg) resulted rn lower 
AUC values as compared to spray 6 (1.25 U/kg) and in higher values 
as compared to that found using the newperfusion 
We have compared s.c. and nasal route of insulin 
administration using response measurements (relative efficacy or 
apparent bioavailability), rather than plasma insulin concentrations 
(bioavailability). The merits of using this method are in the 
simplicity of the plasma glucose determinations and that efficacy 
(apparent bioavailability) is the parameter most relative to 
therapeutics. Although relative efficacy could be expected to be 
similar to bioavailability, this can not be assumed. Table 12 
summarizes the apparent pharmacokinetic parameters obtained for 
the different modes of administration. The apparent bioavailability 
was calculated assuming that the effect observed for s.c. injection of 
insulin was 100%. The apparent bioavailabilities observed for spray 
3 (IOU/kg), spray 4 (5U/kg), spray 5 (2.5U/kg) and spray 6 
(1.25U/kg) were 3.44, 6.49, 9.41 and 18.24% respectively. The 
apparent bioavailability increased gradually from spray 3 (3.44%) to 
spray 6 (18.24%) . The relative absorption of insulin was higher for 
1.25 U/kg spray when compared to 10 U/kg spray. The probable 
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reasons for this nonlinearity may be due to the fact that the 
transport of insulin across the nasal membrane is following 
saturation kinetics (Anik et al., 1984 ). In other words, the amount of 
insulin that could be absorbed across the mucosal membrane is 
limited and hence an increase in insulin dose did not result in 
proportional increase in A UC. Insulin loaded PAA microparticles 
resulted in lower bioavailability (1.88%) compared to spray 
formulations, but a higher bioavailability when compared to the 
perfusion studies using new technique (1.58%). 
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( 5. CONCLUSIONS 
The rabbit was used as an animal model to develop a non -
surgical perfusion technique. Insulin was utilized as a model 
polypeptide drug . The results of this study indicated that the new 
non-surgical perfusion technique can be used to evaluate the nasal 
absorption potential of insulin in rabbits. The new non-surgical 
perfusion technique was compared with that developed by Mehta et 
al. (1990). The absorption of insulin was measured by the changes 
observed in blood glucose levels. Various nasal formulations were 
also evaluated using the rabbit as an animal model. The apparent 
bioavailabilities for the vanous formulations/dosage forms were 
determined based on the effect observed after subcutaneous 
injection of insulin. The results of this investigation can be 
summarized as follows: 
(1) A new non-surgical perfusion technique was developed and 
established using the rabbit as animal model. 
(2) The new non-surgical perfusion technique was comparable to the 
existing non-surgical perfusion technique. The new technique was 
found to offer certain advantages compared to the old one. These 
include reusability of the animal, simplicity of the technique and 
reproducibility of the results. Further studies are required to 
completely characterize this new technique. 
(3) The study conditions needed to characterize the rabbit model 
during the perfusion studies were identified. These include the angle 
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( at which rabbit head is placed, the perfusion rate, the volume of the 
perfusate, the amount of the enhancer present in the perfusion 
solution and the pH of the solution. 
( 4) Spray formulations containing different levels of insulin were 
evaluated in the same animal model. The nasal sprays administered 
by spray pump resulted in immediate reduction of glucose levels. 
The maximum hypoglycemic effect was observed approximately 60 
minutes after administration. As the dose was increased from 1.5 
U/kg to 10 U/kg, there was an increased reduction in blood glucose 
levels. However, the glucose reduction was not proportional to the 
insulin dose. The PAA gel formulation containing insulin loaded 
microparticles resulted in a hypoglycemic effect but the overall 
effect was less compared to the spray formulations. As expected the 
subcutaneous injection of insulin (0.25 U/kg) resulted in slower 
absorption of insulin when compared to nasal sprays. 
(5) The spray formulations tested caused a higher hypoglycemic 
effect when compared to perfusion solutions most probably due to 
higher amount of enhancer present in the spray formulations. 
(6) The apparent bioavailability was calculated based on the AUC 
values obtained from the mean differences in glucose levels from 
those of the controls. The apparent bioavailability increased for 
spray formulations as the dose of insulin was decreased. A maximum 
apparent bioavailability of 18.8% was observed at a dose of 1.25 
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( U/kg. The lowest values were observed for the perfusion study 
carried out by the new technique. 
(7) A split-plot design was used to evaluate the treatment effects. 
When compared to the controls, sprays, insulin loaded PAA 
microparticles, s.c. and perfusion experiments resulted in significant 
reductions in blood glucose levels at 95% confidence level. 
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